53 results on '"Jauch KW"'
Search Results
2. DEPRESSED T-CELL FUNCTION IS RESPONSIBLE FOR DIMINISHED CELL-MEDIATED IMMUNRESPONSES FOLLOWING TRAUMA-HEMORRHAGE.
- Author
-
Walz, Cr, Zedler, S, Schneider, C, Mayr, S, Faist, E, Chaudry, Ih, Jauch, Kw, and Angele, Mk
- Published
- 2006
- Full Text
- View/download PDF
3. Allocation of Organs Should be Based on the Current Status of Medical Science.
- Author
-
Reichart B, Schroth U, and Jauch KW
- Subjects
- Humans, Resource Allocation, Tissue and Organ Procurement, Waiting Lists
- Published
- 2017
- Full Text
- View/download PDF
4. miR-221 Mediates Chemoresistance of Esophageal Adenocarcinoma by Direct Targeting of DKK2 Expression.
- Author
-
Wang Y, Zhao Y, Herbst A, Kalinski T, Qin J, Wang X, Jiang Z, Benedix F, Franke S, Wartman T, Camaj P, Halangk W, Kolligs FT, Jauch KW, Nelson PJ, and Bruns CJ
- Subjects
- Adenocarcinoma drug therapy, Adenocarcinoma pathology, Animals, Cell Culture Techniques, Disease Models, Animal, Esophageal Neoplasms drug therapy, Esophageal Neoplasms pathology, Humans, Male, Mice, Mice, Inbred BALB C, Adenocarcinoma metabolism, Antimetabolites, Antineoplastic therapeutic use, Drug Resistance, Neoplasm, Esophageal Neoplasms metabolism, Fluorouracil therapeutic use, Intercellular Signaling Peptides and Proteins physiology, MicroRNAs metabolism
- Abstract
Background: Chemoresistance is a main obstacle to effective esophageal cancer (EC) therapy. We hypothesize that altered expression of microRNAs (miRNAs) play a role in EC cancer progression and resistance to 5-fluorouracil (5-FU) based chemotherapeutic strategies., Methods: Four pairs of esophageal adenocarcinoma (EAC) cell lines and corresponding 5-FU resistant variants were established. The expression levels of miRNAs previously shown to be involved in the general regulation of stem cell pathways were analyzed by qRT-PCR. The effects of selected miRNAs on proliferation, apoptosis, and chemosensitivity were evaluated both in vitro and in vivo. We identified a particular miRNA and analyzed its putative target genes in 14 pairs of human EC tumor specimens with surrounding normal tissue by qRT-PCR as well as Wnt pathway associated genes by immunohistochemistry in another 45 EAC tumor samples., Results: MiR-221 was overexpressed in 5-FU resistant EC cell lines as well as in human EAC tissue. DKK2 was identified as a target gene for miR-221. Knockdown of miR-221 in 5-FU resistant cells resulted in reduced cell proliferation, increased apoptosis, restored chemosensitivity, and led to inactivation of the Wnt/β-catenin pathway mediated by alteration in DKK2 expression. Moreover, miR-221 reduction resulted in alteration of EMT-associated genes such as E-cadherin and vimentin as well as significantly slower xenograft tumor growth in nude mice. RT profiler analysis identified a substantial dysregulation of 4 Wnt/β-catenin signaling and chemoresistance target genes as a result of miR-221 modulation: CDH1, CD44, MYC, and ABCG2., Conclusion: MiR-221 controls 5-FU resistance of EC partly via modulation of Wnt/β-catenin-EMT pathways by direct targeting of DKK2 expression. MiR-221 may serve as a prognostic marker and therapeutic target for patients with 5-FU resistant EAC.
- Published
- 2016
- Full Text
- View/download PDF
5. Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.
- Author
-
Geissler EK, Schnitzbauer AA, Zülke C, Lamby PE, Proneth A, Duvoux C, Burra P, Jauch KW, Rentsch M, Ganten TM, Schmidt J, Settmacher U, Heise M, Rossi G, Cillo U, Kneteman N, Adam R, van Hoek B, Bachellier P, Wolf P, Rostaing L, Bechstein WO, Rizell M, Powell J, Hidalgo E, Gugenheim J, Wolters H, Brockmann J, Roy A, Mutzbauer I, Schlitt A, Beckebaum S, Graeb C, Nadalin S, Valente U, Turrión VS, Jamieson N, Scholz T, Colledan M, Fändrich F, Becker T, Söderdahl G, Chazouillères O, Mäkisalo H, Pageaux GP, Steininger R, Soliman T, de Jong KP, Pirenne J, Margreiter R, Pratschke J, Pinna AD, Hauss J, Schreiber S, Strasser S, Klempnauer J, Troisi RI, Bhoori S, Lerut J, Bilbao I, Klein CG, Königsrainer A, Mirza DF, Otto G, Mazzaferro V, Neuhaus P, and Schlitt HJ
- Subjects
- Adult, Age Factors, Aged, Australia, Canada, Carcinoma, Hepatocellular mortality, Carcinoma, Hepatocellular pathology, Disease Progression, Disease-Free Survival, Drug Therapy, Combination, Europe, Female, Humans, Intention to Treat Analysis, Kaplan-Meier Estimate, Liver Neoplasms mortality, Liver Neoplasms pathology, Male, Middle Aged, Neoplasm Recurrence, Local, Prospective Studies, Risk Assessment, Risk Factors, TOR Serine-Threonine Kinases antagonists & inhibitors, TOR Serine-Threonine Kinases metabolism, Time Factors, Treatment Outcome, Young Adult, Carcinoma, Hepatocellular surgery, Immunosuppressive Agents therapeutic use, Liver Neoplasms surgery, Liver Transplantation adverse effects, Liver Transplantation mortality, Sirolimus therapeutic use
- Abstract
Background: We investigated whether sirolimus-based immunosuppression improves outcomes in liver transplantation (LTx) candidates with hepatocellular carcinoma (HCC)., Methods: In a prospective-randomized open-label international trial, 525 LTx recipients with HCC initially receiving mammalian target of rapamycin inhibitor-free immunosuppression were randomized 4 to 6 weeks after transplantation into a group on mammalian target of rapamycin inhibitor-free immunosuppression (group A: 264 patients) or a group incorporating sirolimus (group B: 261). The primary endpoint was recurrence-free survival (RFS); intention-to-treat (ITT) analysis was conducted after 8 years. Overall survival (OS) was a secondary endpoint., Results: Recurrence-free survival was 64.5% in group A and 70.2% in group B at study end, this difference was not significant (P = 0.28; hazard ratio [HR], 0.84; 95% confidence interval [95% CI], 0.62; 1.15). In a planned analysis of RFS rates at yearly intervals, group B showed better outcomes 3 years after transplantation (HR, 0.7; 95% CI, 0.48-1.00). Similarly, OS (P = 0.21; HR, 0.81; 95% CI, 0.58-1.13) was not statistically better in group B at study end, but yearly analyses showed improvement out to 5 years (HR, 0.7; 95% CI, 0.49-1.00). Interestingly, subgroup (Milan Criteria-based) analyses revealed that low-risk, rather than high-risk, patients benefited most from sirolimus; furthermore, younger recipients (age ≤60) also benefited, as well sirolimus monotherapy patients. Serious adverse event numbers were alike in groups A (860) and B (874)., Conclusions: Sirolimus in LTx recipients with HCC does not improve long-term RFS beyond 5 years. However, a RFS and OS benefit is evident in the first 3 to 5 years, especially in low-risk patients. This trial provides the first high-level evidence base for selecting immunosuppression in LTx recipients with HCC.
- Published
- 2016
- Full Text
- View/download PDF
6. Effectiveness of regional hyperthermia with chemotherapy for high-risk retroperitoneal and abdominal soft-tissue sarcoma after complete surgical resection: a subgroup analysis of a randomized phase-III multicenter study.
- Author
-
Angele MK, Albertsmeier M, Prix NJ, Hohenberger P, Abdel-Rahman S, Dieterle N, Schmidt M, Mansmann U, Bruns CJ, Issels RD, Jauch KW, and Lindner LH
- Subjects
- Abdomen, Adolescent, Adult, Aged, Chemotherapy, Adjuvant, Disease-Free Survival, Female, Humans, Male, Middle Aged, Prospective Studies, Risk Factors, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Hyperthermia, Induced methods, Retroperitoneal Neoplasms therapy, Sarcoma therapy
- Abstract
Objective: To determine whether regional hyperthermia (RHT) in addition to chemotherapy improves local tumor control after macroscopically complete resection of abdominal or retroperitoneal high-risk sarcomas., Background: Within the prospectively randomized EORTC 62961 phase-III trial, RHT and systemic chemotherapy significantly improved local progression-free survival (LPFS) and disease-free survival (DFS) in patients with abdominal and extremity sarcomas. That trial included macroscopically complete and R2 resections., Methods: A subgroup analysis of the EORTC trial was performed and long-term survival determined. From 341 patients, 149 (median age 52 years, 18-69) were identified with macroscopic complete resection (R0, R1) of abdominal and retroperitoneal soft-tissue sarcomas (median diameter 10 cm, G2 48.3%, G3 51.7%). Seventy-six patients were treated with EIA (etoposide, ifosfamide, doxorubicin)+RHT (≥5 cycles: 69.7%) versus 73 patients receiving EIA alone (≥5 cycles: 52.1%, P=0.027). LPFS and DFS as well as overall survival were determined., Results: RHT and systemic chemotherapy significantly improved LPFS (56% vs 45% after 5 years, P=0.044) and DFS (34% vs 27% after 5 years, P=0.040). Overall survival was not significantly improved in the RHT group (57% vs 55% after 5 years, P=0.82). Perioperative morbidity and mortality were not significantly different between groups., Conclusions: In patients with macroscopically complete tumor resection, RHT in addition to chemotherapy resulted in significantly improved local tumor control and DFS without increasing surgical complications. Within a multimodal therapeutic concept for abdominal and retroperitoneal high-risk sarcomas, RHT is a treatment option beside radical surgery and should be further evaluated in future trials.
- Published
- 2014
- Full Text
- View/download PDF
7. Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer: a dose-finding study.
- Author
-
Joka M, Boeck S, Zech CJ, Seufferlein T, Wichert Gv, Licht T, Krause A, Jauch KW, Heinemann V, and Bruns CJ
- Subjects
- Adenocarcinoma blood supply, Adenocarcinoma pathology, Aged, Aged, 80 and over, Angiogenesis Inhibitors administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Cohort Studies, Deoxycytidine administration & dosage, Deoxycytidine analogs & derivatives, Everolimus, Female, Humans, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Metastasis, Pancreas blood supply, Pancreatic Neoplasms blood supply, Pancreatic Neoplasms pathology, Sirolimus administration & dosage, Sirolimus analogs & derivatives, TOR Serine-Threonine Kinases metabolism, Gemcitabine, Adenocarcinoma drug therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Neovascularization, Pathologic drug therapy, Pancreatic Neoplasms drug therapy, TOR Serine-Threonine Kinases antagonists & inhibitors
- Abstract
Pancreatic adenocarcinomas are associated with a poor survival prognosis. Besides curative surgical resection, only limited therapies with modest impact are available. New evidence suggests that the mammalian target of rapamycin pathway may be involved in the pathogenesis of neuroendocrine tumors, and breast and renal cell cancer. The phase I study described here was therefore designed to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of escalating doses of the mammalian target of rapamycin inhibitor everolimus in combination with gemcitabine in patients with advanced pancreatic cancer. Eligible patients had histologically confirmed locally advanced and/or metastatic pancreatic carcinoma and were administered 5 mg everolimus every second day (cohort 1, 2, 3) or 5 mg daily (cohort 4, 5) in combination with escalating low-dose gemcitabine. It was found that if two patients showed DLTs, MTD was reached and gemcitabine dose escalation was stopped at this level. Twenty-seven patients were enrolled in the study (cohort 1: n=3; cohort 2: n=4; cohort 3: n=6; cohort 4: n=7; cohort 5: n=7) and received a maximum 600 mg gemcitabine/week. In cohort 5, two of the six patients experienced DLTs (grade 3 liver toxicity lasting for>7 days). MTD was measured as 400 mg/m/week gemcitabine plus 5 mg/day everolimus. The MTD of a low-dose gemcitabine treatment in combination with everolimus was determined and no new safety concerns were identified in patients with advanced pancreatic cancer.
- Published
- 2014
- Full Text
- View/download PDF
8. Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? a systematic review and meta-analysis.
- Author
-
Andrassy J, Hoffmann VS, Rentsch M, Stangl M, Habicht A, Meiser B, Fischereder M, Jauch KW, and Guba M
- Subjects
- Antiviral Agents administration & dosage, Cytomegalovirus Infections drug therapy, Cytomegalovirus Infections epidemiology, Humans, Incidence, Organ Transplantation statistics & numerical data, Postoperative Complications epidemiology, Postoperative Complications immunology, Cytomegalovirus Infections prevention & control, Immunosuppressive Agents administration & dosage, Organ Transplantation adverse effects, Postoperative Complications virology, TOR Serine-Threonine Kinases antagonists & inhibitors
- Abstract
Background: Cytomegalovirus (CMV) is a common opportunistic infection after solid organ transplantation. Cytomegalovirus causes increased morbidity, mortality, and reduced allograft survival. Prophylaxis may help control the virus but is associated with substantial side effects and does not completely prevent virus reactivation; relapses after cessation of the prophylaxis are frequent. Experimental and clinical data suggest that mTOR inhibitors may have an anti-CMV effect. Here, we present a meta-analysis of clinical trials after solid organ transplantation and describe potential mechanisms involved in the anti-CMV effect of mTOR-inhibitors., Methods: The current literature was reviewed for randomized controlled trials in solid organ transplantation comparing an mTOR-I with a non-mTOR-I (CNI based) treatment. The scientific quality of the trials was assessed by the Jadad score, the use of an effective allocation concealment (AC) and the existence of an intention-to-treat (ITT) analysis. Cytomegalovirus incidence was assessed in studies comparing 1) an mTOR-I-based with a CNI-based immunosuppression (10 trials, n=3,100 patients) and 2) an mTOR-I/CNI combination therapy with a CNI-based immunosuppression (15 trials, n=7,100 patients)., Results: In the first meta-analysis, CMV events after solid organ transplantation occurred significantly more often under CNIs (RR=2.27). The second meta-analysis comparing the mTOR-I + CNI combination with a CNI treatment in 15 trials of kidney, heart, and liver transplantation showed again a higher CMV incidence when patients received an mTOR-I free immunosuppression (RR=2.45)., Conclusions: mTOR-inhibitor treatment either alone or in combination with CNIs reduces significantly the CMV incidence after organ transplantation. With the use of an mTOR-inhibitor, CMV prophylaxis may be dispensible.
- Published
- 2012
- Full Text
- View/download PDF
9. Selective targeting of genetically engineered mesenchymal stem cells to tumor stroma microenvironments using tissue-specific suicide gene expression suppresses growth of hepatocellular carcinoma.
- Author
-
Niess H, Bao Q, Conrad C, Zischek C, Notohamiprodjo M, Schwab F, Schwarz B, Huss R, Jauch KW, Nelson PJ, and Bruns CJ
- Subjects
- Animals, Antiviral Agents therapeutic use, Carcinoma, Hepatocellular genetics, Carcinoma, Hepatocellular physiopathology, Cell Differentiation, Cell Proliferation, Chemokine CCL5 genetics, Disease Models, Animal, Female, Ganciclovir therapeutic use, Genetic Engineering, Liver Neoplasms, Experimental genetics, Liver Neoplasms, Experimental physiopathology, Mice, Mice, Inbred C57BL, Neovascularization, Pathologic, Receptor Protein-Tyrosine Kinases genetics, Receptor, TIE-2, Transfection, Transplantation, Heterologous, Carcinoma, Hepatocellular therapy, Genes, Transgenic, Suicide genetics, Genetic Therapy methods, Liver Neoplasms, Experimental therapy, Mesenchymal Stem Cell Transplantation methods, Mesenchymal Stem Cells metabolism, Tumor Microenvironment
- Abstract
Background: The use of engineered mesenchymal stem cells (MSCs) as therapeutic vehicles for the treatment of experimental pancreatic and breast cancer has been previously demonstrated. The potential application of MSCs for the treatment of hepatocellular carcinoma (HCC) has been controversial. The general approach uses engineered MSCs to target different aspects of tumor biology, including angiogenesis or the fibroblast-like stromal compartment, through the use of tissue-specific expression of therapeutic transgenes. The aim of the present study was (1) to evaluate the effect of exogenously added MSCs on the growth of HCC and (2) the establishment of an MSC-based suicide gene therapy for experimental HCC., Methods: Mesenchymal stem cells were isolated from bone marrow of C57/Bl6 p53(-/-) mice. The cells were injected into mice with HCC xenografts and the effect on tumor proliferation and angiogenesis was evaluated. The cells were then stably transfected with red fluorescent protein (RFP) or Herpes simplex virus thymidine kinase (HSV-Tk) gene under control of the Tie2 promoter/enhancer or the CCL5 promoter. Mesenchymal stem cells were injected intravenously into mice with orthotopically growing xenografts of HCC and treated with ganciclovir (GCV)., Results: Ex vivo examination of hepatic tumors revealed tumor-specific recruitment, enhanced tumor growth, and increased microvessel density after nontherapeutic MSC injections. After their homing to the hepatic xenografts, engineered MSCs demonstrated activation of the Tie2 or CCL5 promoter as shown by RFP expression. Application of CCL5/HSV-TK transfected MSCs in combination with GCV significantly reduced tumor growth by 56.4% as compared with the control group and by 71.6% as compared with nontherapeutic MSC injections. CCL5/HSV-TK(+) transfected MSCs proved more potent in tumor inhibition as compared with Tie2/HSV-TK(+) MSCs., Conclusion: Exogenously added MSCs are recruited to growing HCC xenografts with concomitant activation of the CCL5 or Tie2 promoters within the MSCs. Stem cell-mediated introduction of suicide genes into the tumor followed by prodrug administration was effective for treatment of experimental HCC and thus may help fill the existing gap in bridging therapies for patients suffering from advanced HCCs.
- Published
- 2011
- Full Text
- View/download PDF
10. Targeted endothelial delivery of nanosized catalase immunoconjugates protects lung grafts donated after cardiac death.
- Author
-
Preissler G, Loehe F, Huff IV, Ebersberger U, Shuvaev VV, Bittmann I, Hermanns I, Kirkpatrick JC, Fischer K, Eichhorn ME, Winter H, Jauch KW, Albelda SM, Muzykantov VR, and Wiewrodt R
- Subjects
- Animals, Antibodies administration & dosage, Death, Drug Delivery Systems, Endothelial Cells immunology, Humans, Lung Transplantation pathology, Lung Transplantation physiology, Nanoparticles administration & dosage, Oxidative Stress, Platelet Endothelial Cell Adhesion Molecule-1 immunology, Pulmonary Gas Exchange, Sus scrofa, Tissue Donors, Catalase administration & dosage, Immunoconjugates administration & dosage, Lung Transplantation methods, Organ Preservation methods
- Abstract
Background: Donor organ shortage represents a major problem in lung transplantation. Donation after cardiac death could help to expand the pool of organs, but the additional period of warm ischemia after cardiac arrest aggravates primary graft dysfunction. The pulmonary endothelium of the graft constitutes an important source and target of reactive oxygen species generated during ischemia and reperfusion. Targeted protection of graft pulmonary endothelial cells by the antioxidant enzyme catalase, conjugated with a platelet/endothelial cell adhesion molecule-1 (PECAM-1) antibody to nanosized particles (anti-PECAM/catalase conjugates), might improve outcome in lung transplantation using donors after cardiac death and prolonged hypothermic preservation., Methods: Left lung transplantation was performed in 18 pigs. Before cardiac arrest, donors received anti-PECAM/catalase, unconjugated component mixture or vehicle solution. After 90-min warm and 18-hr hypothermic ischemia, lungs were transplanted, and function was assessed during 6 hr after reperfusion. Samples of bronchoalveolar lavage fluid and lung tissue were taken thereafter. Six sham-operated animals served as controls., Results: During 6-hr reperfusion, anti-PECAM/catalase significantly ameliorated graft function, evidenced by major improvements of gas exchange and reduced intrapulmonary shunt fraction. Furthermore, lipid peroxidation, alveolar leakage, and edema formation were reduced in protected grafts. Similarly moderate lung pathology was seen after transplantation., Conclusions: Augmentation of the antioxidant capacity of graft pulmonary endothelial cells with anti-PECAM/catalase nanoparticles represents a straightforward approach to enable a safe transplantation of prolonged preserved donation after cardiac death lungs. Anti-PECAM/catalase protection alleviated oxidative stress and allowed immediate reconstitution of normal gas exchange and pulmonary microcirculation, a prerequisite for improved graft and patient outcome.
- Published
- 2011
- Full Text
- View/download PDF
11. Linking transgene expression of engineered mesenchymal stem cells and angiopoietin-1-induced differentiation to target cancer angiogenesis.
- Author
-
Conrad C, Hüsemann Y, Niess H, von Luettichau I, Huss R, Bauer C, Jauch KW, Klein CA, Bruns C, and Nelson PJ
- Subjects
- Animals, Female, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Transgenic, Neovascularization, Pathologic pathology, Receptor Protein-Tyrosine Kinases genetics, Receptor, TIE-2, Simplexvirus genetics, Adenocarcinoma genetics, Adenocarcinoma pathology, Angiopoietin-1 pharmacology, Cell Transformation, Neoplastic genetics, Cell Transformation, Neoplastic pathology, Gene Expression genetics, Gene Targeting, Genes, Reporter genetics, Genes, Transgenic, Suicide genetics, Genetic Engineering, Genetic Therapy methods, Mammary Neoplasms, Experimental genetics, Mammary Neoplasms, Experimental pathology, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells metabolism, Neovascularization, Pathologic genetics, Pancreatic Neoplasms genetics, Pancreatic Neoplasms pathology, Thymidine Kinase genetics, Transgenes genetics
- Abstract
Objective: To specifically target tumor angiogenesis by linking transgene expression of engineered mesenchymal stem cells to angiopoietin-1-induced differentiation., Background: Mesenchymal stem cells (MSCs) have been used to deliver therapeutic genes into solid tumors. These strategies rely on their homing mechanisms only to deliver the therapeutic agent., Methods: We engineered murine MSC to express reporter genes or therapeutic genes under the selective control of the Tie2 promoter/enhancer. This approach uses the differentiative potential of MSCs induced by the tumor microenvironment to drive therapeutic gene expression only in the context of angiogenesis., Results: When injected into the peripheral circulation of mice with either, orthotopic pancreatic or spontaneous breast cancer, the engineered MSCs were actively recruited to growing tumor vasculature and induced the selective expression of either reporter red florescent protein or suicide genes [herpes simplex virus-thymidine kinase (TK) gene] when the adoptively transferred MSC developed endothelial-like characteristics. The TK gene product in combination with the prodrug ganciclovir (GCV) produces a potent toxin, which affects replicative cells. The homing of engineered MSC with selective induction of TK in concert with GCV resulted in a toxic tumor-specific environment. The efficacy of this approach was demonstrated by significant reduction in primary tumor growth and prolongation of life in both tumor models., Conclusion: This "Trojan Horse" combined stem cell/gene therapy represents a novel treatment strategy for tailored therapy of solid tumors.
- Published
- 2011
- Full Text
- View/download PDF
12. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial.
- Author
-
Guba M, Pratschke J, Hugo C, Krämer BK, Nohr-Westphal C, Brockmann J, Andrassy J, Reinke P, Pressmar K, Hakenberg O, Fischereder M, Pascher A, Illner WD, Banas B, and Jauch KW
- Subjects
- Acne Vulgaris chemically induced, Adrenal Cortex Hormones therapeutic use, Adult, Creatinine blood, Drug Therapy, Combination, Female, Follow-Up Studies, Glomerular Filtration Rate, Graft Survival immunology, Humans, Hyperlipidemias chemically induced, Immunosuppressive Agents therapeutic use, Kidney Failure, Chronic etiology, Kidney Failure, Chronic surgery, Male, Middle Aged, Mycophenolic Acid therapeutic use, Patient Selection, Prospective Studies, Safety, Sirolimus adverse effects, Time Factors, Tissue Donors statistics & numerical data, Antilymphocyte Serum therapeutic use, Calcineurin Inhibitors, Kidney Transplantation immunology, Mycophenolic Acid analogs & derivatives, Sirolimus therapeutic use
- Abstract
Background: De novo sirolimus in calcineurin inhibitor-free regimens, although potentially useful to improve early renal function, are complicated by various drug-related side effects., Methods: We report a prospective open-label, multicenter, randomized trial to evaluate early conversion from a CsA-based to a sirolimus (SRL)-based regimen 10 to 24 days after renal transplantation. Of the 196 patients, 141 patients with a low-to-moderate immunological risk were eligible to be converted to SRL or to continue CsA. All patients received antithymocyte globulin-F single-bolus induction, mycophenolate mofetil, and steroids., Results: The primary endpoint, renal function determined by S-creatinine and estimated glomerular filtration rate calculated by Nankivell formula at 12 months was significantly better in the SRL group (1.51+/-0.59 vs. 1.87+/-0.98 mg/dL or 64.5+/-25.2 vs. 53.4+/-18.0 mL/min/1.73 m). Patient survival, graft survival, and incidence of biopsy-proven acute rejection after conversion were not statistically different. Drug discontinuations were significantly higher in the SRL group (36.2% vs. 19.7%). Significantly, more patients in the SRL group reported acne, aphtous, and temporary hyperlipidemia, whereas cytomegalovirus viremia was significantly decreased (7.3% vs. 28.2%)., Conclusions: Early conversion to a calcineurin inhibitor-free regimen with SRL in combination with mycophenolate mofetil may be a useful strategy to improve renal function. The identification of appropriate candidates and safe management of SRL-related adverse events will be a key to avoid the high rate of dropouts, which currently limit the broad applicability of this protocol.
- Published
- 2010
- Full Text
- View/download PDF
13. The prognostic value of lymph node ratio in a population-based collective of colorectal cancer patients.
- Author
-
Rosenberg R, Engel J, Bruns C, Heitland W, Hermes N, Jauch KW, Kopp R, Pütterich E, Ruppert R, Schuster T, Friess H, and Hölzel D
- Subjects
- Aged, Colorectal Neoplasms mortality, Colorectal Neoplasms therapy, Female, Humans, Lymph Node Excision, Lymphatic Metastasis, Male, Prognosis, Survival Analysis, Colorectal Neoplasms pathology, Lymph Nodes pathology
- Abstract
Objective: We analyzed 3 previously identified cut-off values of lymph node ratios (0.17, 0.41, and 0.69) in a large population-based collective of patients with colorectal cancer for their prognostic value., Summary Background Data: The lymph node ratio (LNR) (relation of tumor-infiltrated to total examined lymph nodes) has a high prognostic impact, but the relevant cut-off values are not determined., Methods: Patients (N = 27,803) with a primary colorectal cancer diagnosed and operated in the Munich region between 1991 and 2006 were registered in the Munich Cancer Registry. Lymph node numbers and survival data were available for 17,309 patients with a mean follow-up of 5.9 years., Results: The mean number (+/-SD) of resected lymph nodes was 16.8 +/- 8.4. Twelve or more lymph nodes were resected in 76.8%. Estimated 5-year overall survival decreased significantly with increasing LNR: LNR = 0 in 71.4%, LNR 0.01 to 0.17 in 52.4%, LNR 0.18 to 0.41 in 33.3%, LNR 0.42 to 0.69 in 19.8%, and LNR > or = 0.70 in 8.3% (P < 0.001). Multivariable survival analyses identified separately both LNR and pN- category, as well as number of resected lymph nodes, patient's age, tumor location, pT-category, pM-status, R-status, tumor grade, and year of operation as independent prognostic factors., Conclusion: : The 3 cut-off values of LNRs had strong independent prognostic value in a population-based collective of patients with colorectal cancer. The LNR should be routinely reported and included in the American Joint Committee on Cancer staging system. Nevertheless, the benefit of lymphadenectomy on survival is still unclear.
- Published
- 2010
- Full Text
- View/download PDF
14. Long-term survival after surgical critical illness: the impact of prolonged preceding organ support therapy.
- Author
-
Schneider CP, Fertmann J, Geiger S, Wolf H, Biermaier H, Hofner B, Küchenhoff H, Jauch KW, and Hartl WH
- Subjects
- Acute Kidney Injury therapy, Humans, Intensive Care Units, Prognosis, Respiratory Insufficiency therapy, Shock therapy, Survival Rate, Catecholamines therapeutic use, Critical Care, Critical Illness mortality, Renal Replacement Therapy, Respiration, Artificial
- Abstract
Objective: To identify the prognostic importance of preceding invasive ventilation, renal replacement therapy, and catecholamine therapy for long-term survivors after surgical critical illness., Summary Background Data: Nothing is known about the effect of preceding intensive care unit (ICU)-related therapies on long-term outcome., Methods: We performed a retrospective analysis of prospectively collected data of an ICU patient cohort linked to a local database. Adult patients (n = 1462) admitted to a 12-bed ICU between 1993 and 2005, who had an ICU length of stay of more than 4 days, were followed up until the end of the second year after ICU admission. Hazard function was explored by Weibull modeling and likelihood ratio tests. Cox-type structured hazard regression models were used to analyze linear, nonlinear, or time-varying associations of therapeutic variables with 2-year survival time of a patient subgroup, which had survived the period of high hazard., Results: Hazard rate declined exponentially up to day 195 after ICU admission, and became constant thereafter. A total of 808 patients reached this stable stage of their disease forming the study population. Of these patients, 648 (80.2%) were still alive at the end of the second year after ICU admission. Underlying diseases were major determinants for long-term outcome. Long-term mortality was significantly associated with the acute extent of physiological derangement during ICU stay (maximum Apache II score), but was independent from the duration of preceding invasive organ support., Conclusion: In surgical patients with a prolonged ICU length of stay, an exorbitant mortality exists for about half a year after ICU admission. Later on, life expectancy of surviving patients is largely determined by the underlying disease and, to a minor degree, by the acute extent of homeostatic disturbance during ICU stay. The duration of preceding invasive therapies does not limit long-term survival.
- Published
- 2010
- Full Text
- View/download PDF
15. The intrinsic renal compartment syndrome: new perspectives in kidney transplantation.
- Author
-
Herrler T, Tischer A, Meyer A, Feiler S, Guba M, Nowak S, Rentsch M, Bartenstein P, Hacker M, and Jauch KW
- Subjects
- Animals, Compartment Syndromes etiology, Kidney diagnostic imaging, Kidney Diseases diagnostic imaging, Kidney Diseases pathology, Kidney Transplantation adverse effects, Male, Mice, Mice, Inbred BALB C, Radionuclide Imaging, Reperfusion Injury diagnostic imaging, Reperfusion Injury pathology, Technetium Tc 99m Mertiatide, Compartment Syndromes epidemiology, Kidney Transplantation physiology
- Abstract
Purpose: Inflammatory edema after ischemia-reperfusion may impair renal allograft function after kidney transplantation. This study examines the effect of edema-related pressure elevation on renal function and describes a simple method to relieve pressure within the renal compartment., Methods: Subcapsular pressure at 6, 12, 24, 48 hr, and 18 days after a 45 min warm ischemia was determined in a murine model of renal ischemia-reperfusion injury. Renal function was measured by Tc-MAG3 scintigraphy and laser Doppler perfusion. Structural damage was assessed by histologic analysis. As a therapeutic approach, parenchymal pressure was relieved by a standardized circular 0.3 mm incision at the lower pole of the kidney capsule., Results: Compared with baseline (0.9+/-0.3 mm Hg), prolonged ischemia was associated with a sevenfold increase in subcapsular pressure 6 hr after ischemia (7.0+/-1.0 mm Hg; P<0.001). Pressure levels remained significantly elevated for 24 hr. Without therapy, a significant decrease in functional parameters was found with considerably reduced tubular excretion rate (33+/-3.5%, P<0.001) and renal perfusion (64.5+/-6.8%, P<0.005). Histologically, severe tissue damage was found. Surgical pressure relief was able to significantly prevent loss of tubular excretion rate (62.5+/-6.8%, P<0.05) and renal blood flow (96.2+/-4.8%; P<0.05) and preserved the integrity of renal structures., Conclusions: Our data support the hypothesis of the existence of a renal compartment syndrome as a consequence of ischemia-reperfusion injury. Surgical pressure relief effectively prevented functional and structural renal impairment, and we speculate that this approach might be of value for improving graft function after renal transplantation.
- Published
- 2010
- Full Text
- View/download PDF
16. Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma.
- Author
-
Zischek C, Niess H, Ischenko I, Conrad C, Huss R, Jauch KW, Nelson PJ, and Bruns C
- Subjects
- Animals, Cell Movement, Chemokine CCL5 genetics, Genes, Reporter, Injections, Intraperitoneal, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells physiology, Mice, Mice, Inbred C57BL, Pancreatic Neoplasms pathology, Promoter Regions, Genetic, Simplexvirus genetics, Thymidine Kinase genetics, Thymidine Kinase metabolism, Genes, Transgenic, Suicide, Genetic Therapy, Mesenchymal Stem Cells metabolism, Pancreatic Neoplasms therapy, Tissue Engineering
- Abstract
Objective: To analyze the efficacy of engineered mesenchymal stem cell based therapy directed towards pancreatic tumor stroma., Summary Background Data: Mesenchymal stem cells (MSC) are actively recruited to tumor stroma where they enhance tumor growth and metastases. Upregulation of chemotactic cytokine (CCL5) by MSCs within the tumor stroma has been shown to play a central role in this process. Murine MSCs were engineered to express reporter genes or therapeutic genes under control of the CCL5 promoter and adoptively transferred into mice with growing pancreatic tumors. The effect on tumor growth and metastases was then evaluated., Methods: MSCs isolated from bone marrow of C57/Bl6 p53 mice were stably transfected with red fluorescent protein (RFP), enhanced green fluorescent protein (eGFP), or herpes simplex virus (HSV) thymidine kinase (Tk) gene driven by the RANTES promoter. MSCs were intravenously applied once per week over 3 weeks to mice carrying an orthotopic, syngeneic pancreatic Panc02 tumor., Results: eGFP and RFP signals driven by the CCL5 promoter were detected by fluorescence in treated pancreatic tumor samples. The HSV-Tk therapy group treated intraperitoneal with the prodrug ganciclovir 5 to 7 days after stem cell application lead to a 50% reduction of primary pancreatic tumor growth (P < 0.0003, student t test) and reduced liver metastases (0% vs. 60%)., Conclusion: The active homing of MSCs into primary pancreatic tumor stroma and activation of the CCL5 promoter was verified using eGFP- and RFP-reporter genes. In the presence of ganciclovir, HSV-Tk transfected MSCs led to a significant reduction of primary pancreatic tumor growth and incidence of metastases.
- Published
- 2009
- Full Text
- View/download PDF
17. Recipient treatment with L-arginine attenuates donor lung injury associated with hemorrhagic shock.
- Author
-
Preissler G, Löhe F, Ebersberger U, Huff I, Bittmann I, Messmer K, Jauch KW, and Angele MK
- Subjects
- Animals, Arginine administration & dosage, Blood Pressure, Carotid Artery, External, Catheterization, Central Venous, Humans, Infusions, Intravenous, Lung Transplantation adverse effects, Lung Transplantation physiology, Models, Animal, Organ Preservation methods, Reperfusion Injury prevention & control, Resuscitation adverse effects, Resuscitation methods, Swine, Thoracotomy, Tissue Donors, Arginine therapeutic use, Lung Transplantation pathology, Shock, Hemorrhagic prevention & control
- Abstract
Background: Organ donors are frequently trauma victims, but the impact of donor hemorrhagic shock and resuscitation (HSR) on pulmonary graft function has not been assessed. L-arginine treatment during reperfusion increases the production of endothelial nitric oxide and thus ameliorates ischemia-reperfusion injury. Objective of the present porcine study was to investigate the effect of donor hemorrhage on pulmonary graft function and potential beneficial effects of L-arginine administration., Methods: In the control-group (n=6), lungs were harvested from donors without hypotensive periods. In the HSR-group (n=6) and HSR-Arg-group (n=6), donors were subjected to hemorrhagic shock (40% blood shed) and resuscitation before harvest. Left lungs were transplanted after hypothermic preservation of 18 hr, and graft function was observed for 6 hr after reperfusion. Recipients in the HSR-Arg-group received a bolus of L-arginine (50 mg/kg BW) intravenously 5 min before reperfusion followed by a continuous intravenous administration of L-arginine 200 mg/kg BW for 2 hr. Tissue specimens and bronchoalveolar lavage fluid were obtained at the end of the observation period., Results: Donor lung function did not differ between study groups. Compared with the control group, pulmonary graft gas exchange was significantly impaired in the HSR-group. Graft function in the HSR-Arg-group did not differ from control organs. Neutrophil fraction, protein content, and malondialdehyde levels in the bronchoalveolar lavage fluid in the HSR-group were higher compared with control and HSR-Arg-Group., Conclusion: Although fulfilling ideal donor criteria, pulmonary graft function of lungs harvested from donors subjected to HSR is impaired, but improves significantly when l-arginine is administered during reperfusion.
- Published
- 2009
- Full Text
- View/download PDF
18. Accuracy of procalcitonin for outcome prediction in unselected postoperative critically ill patients.
- Author
-
Schneider CP, Yilmaz Y, Kleespies A, Jauch KW, and Hartl WH
- Subjects
- Adult, Aged, Aged, 80 and over, Area Under Curve, Calcitonin Gene-Related Peptide, Female, Humans, Intensive Care Units, Length of Stay, Male, Middle Aged, Models, Statistical, Postoperative Period, Retrospective Studies, Calcitonin blood, Critical Illness mortality, Protein Precursors blood
- Abstract
The importance of postoperative procalcitonin (PCT) measurements for outcome prediction is currently controversial. Conflicting results have been obtained for patients after polytrauma, sepsis, peritonitis, or cardiac surgery and may result from incomplete adjustment for important confounders or from nonlinear PCT effects. We retrospectively analyzed the association of PCT concentration with postoperative mortality, morbidity, and length of stay in an unselected series of 220 consecutive patients who required postoperative intensive care unit therapy or surveillance. Biochemical markers were measured on the first day after intensive care unit admission. Results were adjusted for various confounding variables (Acute Physiology and Chronic Health Evaluation II score, underlying disease), and test accuracy was evaluated by receiver operating characteristic statistics. We found a significant nonlinear, logarithmic association between PCT concentration and outcome. After adjustment for relevant covariates, PCT was an independent determinant of mortality, combined mortality/morbidity, and postoperative hospital length of stay in survivors. At mortality analysis, the predictive power of PCT was superior to that of Acute Physiology and Chronic Health Evaluation II score and of IL-6 (optimal cutoff point, 1.44 ng/mL; sensitivity, 80.8%; specificity, 80.4%). The use of PCT was comparable to that of other prognostic markers when combined mortality/morbidity were examined. Our results suggest that PCT may deserve further testing as a prognostic tool in unselected, critically ill, surgical patients.
- Published
- 2009
- Full Text
- View/download PDF
19. Multipotent mesenchymal stem cells acquire a lymphendothelial phenotype and enhance lymphatic regeneration in vivo.
- Author
-
Conrad C, Niess H, Huss R, Huber S, von Luettichau I, Nelson PJ, Ott HC, Jauch KW, and Bruns CJ
- Subjects
- Animals, Cell Differentiation physiology, Cell Line, Cell Movement physiology, Endothelium, Lymphatic cytology, Female, Humans, Lymphatic Vessels cytology, Mesenchymal Stem Cells cytology, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Multipotent Stem Cells cytology, Endothelium, Lymphatic physiology, Lymphangiogenesis physiology, Lymphatic Vessels physiology, Mesenchymal Stem Cells physiology, Multipotent Stem Cells physiology, Phenotype, Regeneration physiology
- Abstract
Background: The importance and therapeutic value of stem cells in lymphangiogenesis are poorly understood. We evaluated the potential of human and murine mesenchymal stem cells (MSCs) to acquire a lymphatic phenotype in vitro and to enhance lymphatic regeneration in vivo., Methods and Results: We assessed the lymphendothelial differentiation of human and murine MSCs after induction with supernatant derived from human dermal microvascular endothelial cells, isolated lymphatic endothelial cells, and purified vascular endothelial growth factor (VEGF)-C in vitro. We used human or murine progenitor MSC lines and then characterized the lymphatic phenotype by morphology, migratory capacity, and the expression of lymphatic markers such as Prox-1, podoplanin, Lyve-1, VEGF receptor-2, and VEGF receptor-3. Using a murine lymphatic edema model, we assessed the potential of these cells to form a functional lymphatic vasculature in vivo after injection of syngeneic MSCs. Incubation with supernatant from lymphatic endothelial cells induced an endothelium-like morphology and the expression of lymphendothelial markers in both human and murine MSCs in vitro. MSCs showed migratory activity along a VEGF-C gradient, which was enhanced by VEGF-C conditioning. In vivo, the local application of MSCs resulted in a significant decrease in edema formation (-20.1%; P<0.01 versus untreated tails) after 3 weekly cell injections and restored the drainage of intradermally injected methylene blue after 7 weekly injections., Conclusions: MSCs were capable of expressing a lymphatic phenotype when exposed to lymph-inductive media and purified VEGF-C. Migratory activity toward VEGF-C in vitro suggests homing capability in vivo. Restoration of lymphatic drainage after injection of MSCs in a lymphedema model indicates that MSCs play a role in lymphatic regeneration. The potential clinical application of MSC in wound healing and reduction of lymphatic edema warrants further research.
- Published
- 2009
- Full Text
- View/download PDF
20. Activity-guided antithrombin III therapy in severe surgical sepsis: efficacy and safety according to a retrospective data analysis.
- Author
-
Moubarak P, Zilker S, Wolf H, Hofner B, Kneib T, Küchenhoff H, Jauch KW, and Hartl WH
- Subjects
- Aged, Antithrombin III therapeutic use, Female, Humans, Intensive Care Units, Male, Middle Aged, Multivariate Analysis, Retrospective Studies, Sepsis mortality, Serine Proteinase Inhibitors therapeutic use, Treatment Outcome, Antithrombin III adverse effects, Sepsis drug therapy, Serine Proteinase Inhibitors adverse effects
- Abstract
Recent controlled studies that evaluated the efficacy of an adjuvant antithrombin (AT) III therapy in severe sepsis used a uniform AT-III dose and duration of therapy and did not adjust to the actual AT-III deficit. It was the aim of the present study to explore if surgical patients with severe sepsis might have a treatment benefit from an activity-guided AT-III therapy. We performed a retrospective cohort analysis using an intensive care unit (ICU) database. To examine the effect of AT-III on outcome and on red cell transfusion rate, multivariate generalized additive models (GAMs), Cox-type additive hazard regression models, and propensity score adjustments were used. Five hundred forty-five postoperative surgical patients requiring ICU therapy because of severe sepsis were analyzed. Antithrombin III was given to those patients believed to be at a high risk of dying. Antithrombin III therapy was guided by the individual AT-III activity and aimed at the maintenance of an activity of at least 100%. Antithrombin III supplementation was discontinued after the plasma AT-III activity had been persistently normal without simultaneous AT-III infusion. We found that patients receiving additional AT-III (n = 230) were sicker than those on standard therapy (n = 315; admission Acute physiology and chronic health evaluation II score, 19.8 +/- 7.3 vs. 17.9 +/- 7.1 [mean +/- SD]; P < 0.005). Correspondingly, 28-day mortality was higher in patients who had an additional AT-III therapy than in those on standard therapy (46.3% vs. 36.9%; P < 0.03), as was the number of red cell units transfused during ICU stay (21.5 +/- 26.7 vs. 9.3 +/- 12.1; P < 0.001). At multivariate analysis, there was no significant effect of AT-III therapy on 28-day mortality (GAM: odds ratio, 1.012; 95% confidence interval [CI], 0.651 - 1.573; P = 0.957) and 90-day survival time (Cox-type additive hazard regression: hazard ratio, 1.034; 95% CI, 0.779 - 1.387; P = 0.794). However, AT-III therapy was associated with a significantly higher frequency of red cell unit transfusion (GAM/zero-inflated Poisson: estimate, 1.26; 95% CI, 1.15 - 139; P < 0.001). Our results suggest that there seems to be no relevant effect of an activity-guided AT-III therapy on the prognosis of surgical patients with severe sepsis. However, transfusion frequency rises by AT-III therapy.
- Published
- 2008
- Full Text
- View/download PDF
21. The impact of music on hypermetabolism in critical illness.
- Author
-
Nelson A, Hartl W, Jauch KW, Fricchione GL, Benson H, Warshaw AL, and Conrad C
- Subjects
- Cytokines blood, Homeostasis, Human Growth Hormone blood, Humans, Hydrocortisone blood, Neuroimmunomodulation physiology, Critical Illness therapy, Energy Metabolism physiology, Hypothalamo-Hypophyseal System physiology, Music Therapy methods, Pituitary-Adrenal System physiology
- Abstract
Purpose of Review: Although the literature on complementary therapy, including music, is vast, there are few studies conducted in a scientific fashion exploring physiologic mechanisms. This review summarizes recent evidence on the effects of music on the hypermetabolic response of critical illness., Recent Findings: Music may restore some of the distorted homeostasis observed in ICU patients, as well as reducing pain and the need for sedation. Music likely reduces alterations in the hypothalamic-anterior pituitary-peripheral hormone axes that produce cortisol and growth hormone. Music may also increase growth hormone levels, which can induce decreased production of cytokines such as IL-6 by white blood cells. Further, ovarian steroid secretion may paradoxically protect women by increasing baseline circulating stress hormones, providing an opportunity for music therapy to intervene effectively. Dopaminergic neurotransmission has been implicated as a means by which music can modulate the central nervous system., Summary: Music may play an important role as an adjunct therapy in critical care. However, further studies are necessary to elucidate how music can be further integrated clinically and the precise underlying mechanisms of its beneficial effects.
- Published
- 2008
- Full Text
- View/download PDF
22. Independent determinants of early death in critically ill surgical patients.
- Author
-
Müller MH, Moubarak P, Wolf H, Küchenhoff H, Jauch KW, and Hartl WH
- Subjects
- Blood Coagulation Disorders mortality, Blood Pressure, Body Temperature, Cohort Studies, Critical Care, Erythrocyte Transfusion statistics & numerical data, Humans, Postoperative Hemorrhage mortality, Prognosis, Critical Illness mortality, Postoperative Complications mortality
- Abstract
Abnormalities in cardiocirculatory, respiratory, or coagulatory parameters are frequent after major surgery, but so far, no study has investigated their predictive value for early intensive care unit (ICU) mortality. We aimed to describe and quantify the relation between these parameters that are routinely determined on ICU admission and early death after complex surgery. Individual patient data were available from a local ICU database. We performed a retrospective observational cohort study using prospectively collected data from March 1, 1993, through February 28, 2005. A cohort of 4,214 cases who were admitted to the ICU immediately after operation was analyzed. We studied age, sex, number of red blood cell units transfused on admission day, and admission values for heart rate, systolic blood pressure, hemoglobin concentration, partial thromboplastin time, prothrombin time, respiratory function (Pao2/Fio2 ratio), and body temperature for their association with 4-day mortality. Effects were adjusted for the underlying disease and for disease severity during the first 24 h after admission. We used generalized additive models to fit continuous variables individually before combining them into the final generalized model. We found an independent linear association between the number of transfused red blood cell units, partial thromboplastin time, and body temperature with acute outcome. A smoothed model described the independent interaction between admission blood pressure and early death. Only values of less than 80 mmHg were associated with an increased risk of 4-day mortality. According to these results, bleeding complications after ICU admission should be treated aggressively to prevent early death of the patient. However, normotensive conditions do not seem to be required to prevent early mortality. Whether rapid rewarming may improve outcome needs further rigorous study.
- Published
- 2008
- Full Text
- View/download PDF
23. Immunoglobulin M-enriched human intravenous immunoglobulins reduce leukocyte-endothelial cell interactions and attenuate microvascular perfusion failure in normotensive endotoxemia.
- Author
-
Hoffman JN, Fertmann JM, Vollmar B, Laschke MW, Jauch KW, and Menger MD
- Subjects
- Animals, Cell Adhesion drug effects, Cricetinae, Disease Models, Animal, Endothelial Cells drug effects, Endothelial Cells physiology, Endotoxemia pathology, Endotoxemia physiopathology, Humans, Immunoglobulin G administration & dosage, Immunoglobulin G therapeutic use, Immunoglobulin M administration & dosage, Leukocyte Rolling drug effects, Leukocytes drug effects, Leukocytes physiology, Lipopolysaccharides toxicity, Male, Mesocricetus, Microcirculation drug effects, Microcirculation pathology, Microcirculation physiopathology, Microscopy, Fluorescence, Sepsis pathology, Sepsis physiopathology, Sepsis therapy, Endotoxemia therapy, Immunoglobulin M therapeutic use, Immunoglobulins, Intravenous therapeutic use
- Abstract
Clinical studies indicate potential differences in the efficacy of immunoglobulin (Ig) preparations in patients with sepsis. A recent meta-analysis showed improved survival rates with IgM-enriched Igs. It was the objective of the present study to characterize microcirculatory actions of different clinically used Ig preparations in a rodent endotoxin model by intravital microscopy. Male Syrian golden hamsters 6 to 8 weeks old with a body weight of 60 to 80 g were investigated by intravital fluorescence microscopy. Endotoxemia was induced by administration of 2 mg/kg (i.v.) endotoxin (LPS, Escherichia coli). Two different Ig preparations containing IgM, IgA, and IgG (intravenous IgM group; n = 6; 5 mL Pentaglobin/kg body weight, i.v.) or exclusively IgG (intravenous IgG group; n = 5; 5 mL Flebogamma/kg body weight, i.v.) were applied 5 min before LPS. Saline-treated endotoxemic animals served as controls (control; n = 8). In controls, LPS induced massive leukocyte-endothelial cell interactions, pronounced microvascular leakage, a decrease of systemic platelet count, and distinct capillary perfusion failure (P < 0.05). Both intravenous IgM and IgG reduced venular leakage (P< 0.05) and ameliorated the decrease in platelet count (P < 0.05). Of interest, intravenous IgM was capable of significantly (P< 0.05) reducing leukocyte adhesion in venules. This was associated with normalization of capillary perfusion at 24 h of endotoxemia, whereas intravenous IgG could not prevent LPS-mediated microvascular perfusion failure. We demonstrate that IgM-enriched Igs are superior to IgG alone in attenuating LPS-induced leukocytic inflammation and microcirculatory dysfunction. Our findings can explain better efficacy of IgM-enriched Igs in patients with severe sepsis.
- Published
- 2008
- Full Text
- View/download PDF
24. Overture for growth hormone: requiem for interleukin-6?
- Author
-
Conrad C, Niess H, Jauch KW, Bruns CJ, Hartl W, and Welker L
- Subjects
- Aged, Blood Pressure, Critical Illness psychology, Dehydroepiandrosterone blood, Epinephrine blood, Female, Humans, Hypnotics and Sedatives administration & dosage, Hypothalamo-Hypophyseal System, Male, Middle Aged, Models, Biological, Pituitary-Adrenal System, Propofol administration & dosage, Relaxation Therapy, Respiration, Artificial, Stress, Physiological blood, Stress, Physiological physiopathology, Critical Illness therapy, Human Growth Hormone blood, Interleukin-6 blood, Music Therapy, Neuroimmunomodulation physiology, Stress, Physiological prevention & control
- Abstract
Background: Music has been used for therapeutic purposes since the beginning of cultural history. However, despite numerous descriptions of beneficial effects, the precise mechanisms by which music may improve human well-being remain unclear., Methods: We conducted a randomized study in ten critically ill patients to identify mechanisms of music-induced relaxation using a special selection of slow movements of Mozart's piano sonatas. These sonatas were analyzed for compositional elements of relaxation. We measured circulatory variables, brain electrical activity, serum levels of stress hormones and cytokines, requirements for sedative drugs, and level of sedation before and at the end of a 1-hr therapeutic session., Results: Compared with controls, we found that music application significantly reduced the amount of sedative drugs needed to achieve a comparable degree of sedation. Simultaneously, among those receiving the music intervention, plasma concentrations of growth hormone increased, whereas those of interleukin-6 and epinephrine decreased. The reduction in systemic stress hormone levels was associated with a significantly lower blood pressure and heart rate., Conclusion: Based on the effects of slow movements of Mozart's piano sonatas, we propose a neurohumoral pathway by which music might exert its sedative action. This model includes an interaction of the hypothalamic-pituitary axis with the adrenal medulla via mediators of the unspecific immune system
- Published
- 2007
- Full Text
- View/download PDF
25. Red cell transfusion: an essential factor for patient prognosis in surgical critical illness?
- Author
-
Rüttinger D, Wolf H, Küchenhoff H, Jauch KW, and Hartl WH
- Subjects
- Critical Illness, Female, Humans, Length of Stay, Male, Middle Aged, Prognosis, Critical Care, Erythrocyte Transfusion, Surgical Procedures, Operative
- Abstract
In contrast to randomized studies, previous cohort studies identified red cell transfusion as an independent predictor of mortality in critically ill patients. However, these cohort studies did not adjust for disease severity during intensive care unit (ICU) stay. We performed a retrospective, observational cohort study using prospectively collected data from March 1, 1993, through February 28, 2005. A cohort of 3037 consecutive surgical cases requiring intensive care therapy for more than one day was analyzed. We used two different sets of potentially confounding covariables (admission variables only or in combination with variables reflecting number and extent of organ dysfunction during ICU stay). We found that the total number of red cell units which a case had received during ICU stay, and the maximum number of units given on a single day, were independently associated with an increase in ICU mortality when only admission variables were considered for the analysis. After controlling for the additional effect of variables reflecting organ dysfunction during ICU stay, we found that red cell transfusion was no longer an independent risk factor for death. However, there was a significant effect of red cell transfusion on ICU LOS in survivors irrespective of the covariable sets used. We conclude that red cell transfusion during ICU stay may be only a surrogate marker for disease severity and is not causally related to ICU mortality. Relevant side effects of red cell transfusion are presumably small and may be only recognizable in surviving cases.
- Published
- 2007
- Full Text
- View/download PDF
26. Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.
- Author
-
Conrad C, Ischenko I, Köhl G, Wiegand U, Guba M, Yezhelyev M, Ryan AJ, Barge A, Geissler EK, Wedge SR, Jauch KW, and Bruns CJ
- Subjects
- Animals, Antimetabolites, Antineoplastic pharmacology, Blotting, Western, Cell Line, Tumor, Deoxycytidine analogs & derivatives, Deoxycytidine pharmacology, Humans, Immunohistochemistry, Mice, Mice, Nude, Neoplasm Metastasis, Neoplasm Transplantation, Regional Blood Flow drug effects, Signal Transduction drug effects, Skin blood supply, Skin pathology, Transplantation, Heterologous, Gemcitabine, Angiogenesis Inhibitors, Antineoplastic Agents, Enzyme Inhibitors pharmacology, Pancreatic Neoplasms drug therapy, Piperidines pharmacology, Quinazolines pharmacology, Vascular Endothelial Growth Factor Receptor-2 antagonists & inhibitors
- Abstract
ZD6474 is a novel, orally available inhibitor of vascular endothelial growth factor receptor kinase insert domain receptor/flk-1 tyrosine kinase activity with additional activity against the epidermal growth factor receptor-1 tyrosine kinase. The aim of this study was to evaluate ZD6474, alone and in combination with gemcitabine, in an orthotopic model of metastatic pancreatic cancer. Nude mice (nine to 10/group) were injected orthotopically with 1x10(6) L3.6pl human pancreatic cancer cells. Eight days later, treatment was initiated with vehicle only, gemcitabine (100 mg/kg intraperitoneal twice weekly), ZD6474 (50 mg/kg oral once daily) or a combination of the two treatments. Animals were killed on day 24 posttreatment initiation. The phosphorylation status level of vascular endothelial growth factor receptor-2 and epidermal growth factor receptor as well as the phosphorylation level of AKT and extracellular signal-regulated kinase-1/2 in different human pancreatic carcinoma cells and in human umbilical vein endothelial cells was analyzed by Western blotting. Compared with controls (1231 mg), the mean weight of treated tumors was reduced to 836, 541 and 308 mg in the gemcitabine, ZD6474 and combination groups, respectively. Lymph node metastasis was significantly reduced in both the ZD6474 alone and combined treatment groups, with 3/10 and 1/5 animals developing metastases, compared with 10/10 and 9/9 in the control and gemcitabine groups (P<0.003 and <0.0003, respectively). Microvessel density and cell proliferation were significantly reduced in the ZD6474 and combined treatment groups (P<0.02). Immunohistochemistry of tumor samples following treatment with ZD6474 resulted in a reduction of the activated and phosphorylated epidermal growth factor receptor, whereas total epidermal growth factor receptor levels were comparable with control tumors. On the basis of Western blot analysis, ZD6474 provides inhibition of tumor angiogenesis through an anti-vascular endothelial growth factor receptor-2 mechanism and inhibition of cancer cell growth through an anti-epidermal growth factor receptor mechanism. ZD6474 decreased primary pancreatic tumor growth and reduced lymph node and liver metastases compared with controls or gemcitabine alone. Tumor growth was inhibited further in animals receiving ZD6474 and gemcitabine in combination.
- Published
- 2007
- Full Text
- View/download PDF
27. Evaluation of clinical safety and beneficial effects of a fish oil containing lipid emulsion (Lipoplus, MLF541): data from a prospective, randomized, multicenter trial.
- Author
-
Wichmann MW, Thul P, Czarnetzki HD, Morlion BJ, Kemen M, and Jauch KW
- Subjects
- Abdomen surgery, Adult, Aged, Amino Acids blood, Eicosapentaenoic Acid blood, Fat Emulsions, Intravenous, Fatty Acids, Unsaturated blood, Female, Fish Oils adverse effects, Germany, Hospital Mortality, Humans, Intensive Care Units, Length of Stay, Leukotrienes blood, Male, Middle Aged, Phospholipids blood, Postoperative Care, Postoperative Complications blood, Postoperative Complications mortality, Prospective Studies, Survival Rate, Treatment Outcome, alpha-Tocopherol blood, Critical Care, Fish Oils administration & dosage, Parenteral Nutrition, Total
- Abstract
Objective: To prove safety and effectiveness of a lipid emulsion enriched with n-3 fatty acids from fish oil (Lipoplus) within the setting of parenteral nutrition of patients after major abdominal surgery and to determine whether there are effects on outcome parameters., Design: Prospective, randomized, double-blind, multicenter trial., Setting: University and surgical teaching hospitals., Patients: After obtaining informed consent, 256 patients undergoing major abdominal surgery were randomized. Parameters of safety, effectiveness, and outcome were routine laboratory parameters, complication rates, length of stay in the intensive care unit, and length of hospital stay. In addition we determined in patient subgroups of 30 patients each, the changes of the content of selected long-chain polyunsaturated fatty acids, the leukotriene synthetic capacity and the antioxidant alpha-tocopherol., Interventions: Participating patients were randomized to receive either Lipoplus (group I; n = 127 patients) or Intralipid (group II; n = 129 patients). Parenteral nutrition was initiated immediately after surgery and ended on day 5 after surgery., Measurements and Main Results: No significant differences between groups I and II were observed when comparing routine laboratory parameters during the perioperative period. Plasma levels of eicosapentaenoic acid, leukotriene B5, and antioxidant content were significantly increased in group I. Furthermore, there was a significantly shorter length of hospital stay of approximately 21% (17.2 vs. 21.9 days; p = .0061) in group I., Conclusions: Our findings indicate that the administration of Lipoplus in the postoperative period after major abdominal surgery is safe and results in a significantly shorter length of hospital stay. Administration of n-3 polyunsaturated fatty acids in the postoperative period can be considered a valuable choice for patients requiring parenteral nutrition after major abdominal surgery.
- Published
- 2007
- Full Text
- View/download PDF
28. Inhibition of apoptosis reduces immunogeneic potential of adenoviral-treated syngeneic liver grafts.
- Author
-
Puellmann K, Beham A, Kienle K, Vogel M, Schlitt HJ, Jauch KW, and Rentsch M
- Subjects
- Animals, Apoptosis, Genetic Markers, Green Fluorescent Proteins analysis, Green Fluorescent Proteins genetics, In Situ Nick-End Labeling, Liver Transplantation pathology, Male, Proto-Oncogene Proteins c-bcl-2 genetics, Rats, Rats, Inbred Lew, Recombinant Proteins analysis, Reverse Transcriptase Polymerase Chain Reaction, Transplantation, Isogeneic, CD4-Positive T-Lymphocytes immunology, Cytomegalovirus genetics, Liver Transplantation immunology
- Abstract
Effects of adenoviral therapy and reduced apoptosis on immune response were investigated in a rat liver transplantation model after prolonged ischemia-reperfusion. Liver donors were treated i.v. either with an adenoviral construct, expressing bcl-2, green-fluorescent-protein, or doxycyclin. Intrahepatic apoptosis was assessed by terminal transferase dUTP nick end labeling assay. The intrahepatic presence of CD4, CD8a, CD163, immunoglobulin (Ig)beta, tumor necrosis factor (TNF)-alpha and myeloperoxidase (MPO) was quantified by realtime polymerase chain reaction at 24 hours and seven days after transplantation. Bcl-2 expression abrogated the TNF-alpha elevation and reduced apoptosis of hepatocytes and sinusoidal endothelial cells as compared to advCMV green fluorescent protein. No effects on CD4, CD8a, CD163 and MPO expression were noticed in bcl-2 pretreated livers, whereas Igbeta was slightly enhanced compared to controls. Adenoviral infected liver grafts trigger an immune response but reduced apoptosis resulted in down-regulation of TNF-alpha. Thus, bcl-2 transfer might simultaneously reduce graft ischemia reperfusion injury and immunogenicity.
- Published
- 2006
- Full Text
- View/download PDF
29. Microcirculatory disorders in sepsis and transplantation: therapy with natural coagulatory inhibitors antithrombin and activated protein C.
- Author
-
Hoffmann JN, Fertmann JM, and Jauch KW
- Subjects
- Animals, Humans, Models, Animal, Rats, Reperfusion Injury complications, Reperfusion Injury drug therapy, Sepsis complications, Sepsis mortality, Sepsis prevention & control, Anticoagulants pharmacology, Antithrombins pharmacology, Microcirculation drug effects, Organ Transplantation adverse effects, Protein C pharmacology, Sepsis drug therapy
- Abstract
Purpose of Review: Modern technologies allow visualization of microcirculatory disorders. This review describes how the coagulatory inhibitors antithrombin and activated protein C (APC) can improve microcirculation in sepsis and transplantation., Recent Findings: The effects of antithrombin and APC on microcirculatory disorders in ischemia reperfusion and experimental sepsis have been reported recently. In addition, antithrombin has recently been clinically used to reduce graft pancreatitis after pancreas-kidney transplantation, and to improve kidney perfusion. It was demonstrated that septic capillary perfusion failure as well as leukocyte-endothelial cell interactions can be reversed by high-dose prophylactic antithrombin application. APC was also highly effective in this context. Thus, APC could improve microcirculatory blood flow in septic patients as recently measured by in-vivo orthogonal polarization spectral imaging techniques. For antithrombin, comparable measurements in humans are currently not available., Summary: Microcirculatory dysfunction plays a key role in the development of organ dysfunction in septic patients and after solid organ transplantation. The exogenous application of coagulatory inhibitors may provide a new important strategy for prevention and treatment of microcirculatory disorders. This mode of action may be the reason why coagulatory inhibitors could improve mortality in septic patients without directly influencing inflammatory mediator concentrations.
- Published
- 2006
- Full Text
- View/download PDF
30. Stent versus open surgery for acute and chronic traumatic injury of the thoracic aorta: a single-center experience.
- Author
-
Andrassy J, Weidenhagen R, Meimarakis G, Lauterjung L, Jauch KW, and Kopp R
- Subjects
- Adult, Aged, Aged, 80 and over, Aneurysm, False surgery, Aorta, Thoracic surgery, Female, Humans, Injury Severity Score, Length of Stay, Male, Middle Aged, Postoperative Complications, Retrospective Studies, Vascular Surgical Procedures, Aorta, Thoracic injuries, Stents
- Abstract
Background: Traumatic injuries of the thoracic aorta have a high morbidity and mortality. Treatment options include either open surgery or endovascular stent graft implantation., Methods: We have reviewed retrospectively all our patients treated for acute and chronic traumatic injury of the thoracic aorta and compared the outcome of the endovascular versus open therapy. Age, gender, severity of injuries, interventional delay, perioperative morbidity, 30-day mortality, length of intensive care, and overall hospital stay were evaluated., Results: In all, 46 patients were treated over the past 14 years. Overall 30-day mortality was 16% in patients treated for acute or contained aortic ruptures (n = 31) and not significantly different after endovascular versus open repair (13.3% versus 18.8%). There was no mortality in the patients receiving elective stent grafting or open surgery for chronic posttraumatic aortic aneurysms (n = 15). Conversion and/or operative revision following stent graft implantation occurred in three patients (12.5%). Neurologic complications were absent in the stent graft group (0 of 24), whereas paraplegia (n = 2) or minor neurologic (n = 3) deficits developed following open surgery (5 of 22; 22.7%; p = 0.013). Length of intensive care and overall hospital stay were significantly shorter for patients after elective stent graft treatment compared with open surgery (p = 0.045)., Conclusions: According to our midterm results, minimally invasive endovascular repair for patients with acute traumatic ruptures and chronic posttraumatic aneurysms is an equally effective treatment option compared with open surgery, with advantages regarding perioperative neurologic complications and duration of hospital stay under elective circumstances.
- Published
- 2006
- Full Text
- View/download PDF
31. Adenoviral bcl-2 transfer improves survival and early graft function after ischemia and reperfusion in rat liver transplantation.
- Author
-
Rentsch M, Kienle K, Mueller T, Vogel M, Jauch KW, Püllmann K, Obed A, Schlitt HJ, and Beham A
- Subjects
- Adenoviridae genetics, Animals, Apoptosis physiology, Gene Transfer Techniques, In Situ Nick-End Labeling, Male, Rats, Genes, bcl-2, Graft Survival physiology, Liver Transplantation immunology, Reperfusion Injury physiopathology
- Abstract
Background: Primary graft dysfunction due to ischemia and reperfusion injury represents a major problem in liver transplantation. The related cell stress may induce apoptosis, which can be suppressed by bcl-2. The purpose of the study was to investigate the effect of adenoviral bcl-2 gene transfer on early graft function and survival in rat liver transplantation., Methods: An adenoviral construct that transfers bcl-2 under the control of a tetracycline inducible promoter was generated (advTetOn bcl-2) and used with a second adenovirus that transfers the repressor protein (advCMV Rep). Forty-eight hours before explantation, donor rats were treated with advTetOn bcl-2/ advCMV Rep (n=7) and doxycyclin, with the control adenoviral construct advCMV GFP (n=8) or with doxycyclin alone (n=8). Liver transplantation was performed following 16 hours of cold storage (UW). Bcl-2 expression and intrahepatic apoptosis was assessed. Bile flow was monitored 90 min posttransplantation. The endpoint for survival was 7 days., Results: Bcl-2 was expressed in hepatocytes and sinusoidal lining cells. This was associated with a significant reduction of apoptotic sinusoidal lining cells and hepatocytes after 24 hours and 7 days. Bile production was significantly higher following bcl-2 pretreatment. Furthermore, bcl-2 transfer resulted in significantly improved survival (100% vs. 50% both control groups)., Conclusions: Adenoviral bcl-2 transfer results in protein expression in hepatocytes and sinusoidal lining cells resulting in early graft function and survival enhancement after prolonged ischemia and reperfusion injury. The inhibition of apoptosis in the context of liver transplantation might be a reasonable approach in the treatment of graft dysfunction.
- Published
- 2005
- Full Text
- View/download PDF
32. mTOR inhibition and its effect on cancer in transplantation.
- Author
-
Andrassy J, Graeb C, Rentsch M, Jauch KW, and Guba M
- Subjects
- Humans, Immunosuppressive Agents therapeutic use, Neoplasms surgery, Neoplasms therapy, Sirolimus therapeutic use, TOR Serine-Threonine Kinases, Transplantation Immunology, Neoplasms physiopathology, Organ Transplantation physiology, Protein Kinases metabolism
- Abstract
A considerable amount of data indicates that transplanted patients are at increased risk for de novo and recurrent cancer. Treatment of this population is difficult. It remains unclear if the immunosuppressive therapy should be continued, tapered or even stopped or if immunosuppressive drugs with antiproliferative properties have beneficial effects in this situation. In various models, mTOR-inhibitors were shown to have immunosuppressive and anti-tumor effects. Here, we have reviewed the current literature trying to clarify if mTOR-inhibition brings advantages for the transplanted patients suffering from tumors.
- Published
- 2005
- Full Text
- View/download PDF
33. Dehydroepiandrosterone restores depressed peripheral blood mononuclear cell function following major abdominal surgery via the estrogen receptors.
- Author
-
Frantz MC, Prix NJ, Wichmann MW, van den Engel NK, Hernandez-Richter T, Faist E, Chaudry IH, Jauch KW, and Angele MK
- Subjects
- Abdomen surgery, Adult, Aged, Cells, Cultured, Cytokines blood, Estrogen Antagonists pharmacology, Female, Humans, Immunity, Cellular, Immunocompromised Host immunology, Leukocytes, Mononuclear metabolism, Male, Middle Aged, Postoperative Complications prevention & control, Prospective Studies, Sepsis immunology, Sepsis prevention & control, Tamoxifen pharmacology, Adjuvants, Immunologic pharmacology, Dehydroepiandrosterone pharmacology, Immunocompromised Host drug effects, Leukocytes, Mononuclear drug effects, Postoperative Complications immunology, Receptors, Estrogen immunology
- Abstract
Objective: Peripheral blood mononuclear cell (PBMC) dysfunction occurs following major abdominal surgery and correlates with an increased rate of septic complications. Studies have shown that dehydroepiandrosterone (DHEA) restores cell-mediated immune responses after trauma-hemorrhage in mice. Nonetheless, it remains unknown whether DHEA has any salutary effects on depressed PBMC function in surgical patients., Design: Laboratory experiment., Setting: University laboratory., Patients: Fifteen patients undergoing major abdominal surgery., Interventions: Blood samples were obtained preoperatively and 2 hrs postoperatively., Measurements and Main Results: PBMCs were cultured with 33% plasma in the presence or absence of DHEA (10(-10) M, 10(-8) M physiologic concentration, 10(-6) M, 10(-5) M). In an additional set of samples, the estrogen receptor antagonist tamoxifen (10(-6) M) was added. The release of proinflammatory cytokines (interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha) was measured in the supernatants by enzyme-linked immunosorbent assay. Abdominal surgery resulted in depressed interleukin-1beta and tumor necrosis factor-alpha release by PBMC. Addition of DHEA to the culture medium, however, significantly improved the release of interleukin-1beta and tumor necrosis factor-alpha and stimulated the interleukin-6 release capacity of PBMC. This effect was most pronounced for a concentration of 10(-5)M DHEA. The immunomodulatory effect of DHEA on PBMC cytokine release was completely blocked by tamoxifen. In contrast, the modulatory effect of DHEA was enhanced by the addition of postoperative plasma., Conclusions: DHEA stimulates proinflammatory cytokine release capacities of human PBMCs following major abdominal surgery. The estrogen receptor appears to be involved in mediating the immunomodulatory effect of DHEA. Thus, DHEA might be a useful adjunct for preventing immunosuppression in surgical patients.
- Published
- 2005
- Full Text
- View/download PDF
34. L-arginine improves wound healing after trauma-hemorrhage by increasing collagen synthesis.
- Author
-
Wittmann F, Prix N, Mayr S, Angele P, Wichmann MW, van den Engel NK, Hernandez-Richter T, Chaudry IH, Jauch KW, and Angele MK
- Subjects
- Analysis of Variance, Animals, Blotting, Western, Chromatography, High Pressure Liquid, Hydroxyproline metabolism, Male, Mice, Mice, Inbred C3H, Random Allocation, Transforming Growth Factor beta metabolism, Wound Healing immunology, Wounds and Injuries immunology, Arginine pharmacology, Collagen metabolism, Hemorrhage physiopathology, Wound Healing drug effects, Wounds and Injuries drug therapy
- Abstract
Background: Several studies indicate impaired wound healing after trauma and shock. Wound immune cell dysfunction seems to be responsible for altered wound healing after trauma-hemorrhage (T-H). In this respect, administration of the amino acid L-arginine normalized wound immune cell function under those conditions. It remains unknown, however, whether L-arginine improves impaired wound healing after T-H., Methods: To study this, male C3H/HeN mice were subjected to a midline laparotomy (i.e., soft tissue trauma induced), and polyvinyl sponges were implanted subcutaneously at the wound site before hemorrhage (35 +/- 5 mm Hg for 90 minutes) or were subjected to sham operation. During resuscitation, mice received 300 mg/kg body weight L-arginine or saline (vehicle). Seven days thereafter, hydroxyproline (OHP), a metabolite of collagen synthesis, was measured in the wound fluid using high-performance liquid chromatography. Collagen types I and III were determined in the wound by Western blot analysis. In addition, wound breaking strength was measured 10 days after T-H or sham operation., Results: The results indicate that OHP was significantly decreased in T-H mice. L-arginine, however, restored depressed OHP in the wound fluid in the T-H animals. Similarly, L-arginine treatment prevented a significant depression of collagen I synthesis after T-H. Collagen III was not significantly affected by T-H or L-arginine. Most important, L-arginine increased maximal wound breaking strength after severe blood loss. Therefore, L-arginine improves wound healing after T-H by increasing collagen synthesis., Conclusion: Because L-arginine improves wound healing, the results suggest that L-arginine might represent a novel and useful adjunct to fluid resuscitation for decreasing wound complications after trauma and severe blood loss.
- Published
- 2005
- Full Text
- View/download PDF
35. Caspase 3 inhibition improves survival and reduces early graft injury after ischemia and reperfusion in rat liver transplantation.
- Author
-
Mueller TH, Kienle K, Beham A, Geissler EK, Jauch KW, and Rentsch M
- Subjects
- Animals, Apoptosis, Caspase 3, Liver blood supply, Male, Microcirculation pathology, Oligopeptides pharmacology, Poly(ADP-ribose) Polymerases metabolism, Proto-Oncogene Proteins c-bcl-2 analysis, Rats, Rats, Inbred Lew, Caspase Inhibitors, Liver Transplantation mortality, Reperfusion Injury prevention & control
- Abstract
Background: Apoptosis plays a crucial role after ischemia-reperfusion in organ transplantation. It is executed by caspases and influenced by the rheostat of pro- and anti-apoptotic proteins of the bcl-2 family. This study investigated the effect of specific inhibition of caspases 3 and 7 on graft function, survival, and hepatic bcl-2 levels after liver transplantation., Methods: Lewis rats underwent syngeneic orthotopic liver transplantation after 16 hr of cold graft storage (in University of Wisconsin solution). Livers of donor animals treated with D(OMe)E(OMe)VD(OMe)-fluoromethylketone (specific inhibitor of apoptosis executor caspases 3 and 7), and appropriate control groups, were investigated. Early graft injury was quantified by measurement of bile flow and determination of microvascular graft injury by using in vivo fluorescence microscopy. Apoptosis and its regulation were examined by terminal deoxynucleotide transferase-mediated dUTP nick-end labeling staining and Western blot analysis of cell death effectors, respectively., Results: After specific in vivo caspase inhibition, Western blot analysis revealed inhibition of caspase-induced cleavage of poly-ADP-ribose-polymerase. Inhibition of caspases 3 and 7 resulted in a significantly decreased number of apoptotic endothelial cells and improved microvascular perfusion. A cell protective effect was also suggested by an increase of bcl-2 levels at 7 days. Most important, specific caspase blockade resulted in improved rat survival after liver transplantation., Conclusion: Specific inhibition of apoptosis executor caspases effectively reduces graft ischemia-reperfusion injury and improves survival in liver transplantation. Better tissue preservation after caspase inhibition correlates with reduced apoptosis execution, improved microvascular perfusion, and bcl-2 up-regulation. Therefore, specific caspase inhibition represents a promising regimen for clinical use in liver transplantation.
- Published
- 2004
- Full Text
- View/download PDF
36. Insulin treatment improves hepatic morphology and function through modulation of hepatic signals after severe trauma.
- Author
-
Klein D, Schubert T, Horch RE, Jauch KW, and Jeschke MG
- Subjects
- Animals, Apoptosis physiology, Base Sequence, Biopsy, Needle, Cell Division physiology, Cytokines metabolism, Disease Models, Animal, Hepatocytes drug effects, Hepatocytes physiology, Immunohistochemistry, Injury Severity Score, Liver Diseases etiology, Liver Function Tests, Liver Regeneration physiology, Male, Molecular Sequence Data, Polymerase Chain Reaction, RNA, Messenger analysis, Random Allocation, Rats, Rats, Sprague-Dawley, Reference Values, Risk Factors, Sensitivity and Specificity, Apoptosis drug effects, Burns pathology, Insulin pharmacology, Liver Diseases drug therapy, Liver Diseases pathology, Liver Regeneration drug effects
- Abstract
Objective: The purpose of the present study was to determine the effect of insulin therapy on hepatic function, structure, and hepatic mRNA and protein cytokine expression during the hypermetabolic cascade post burn., Summary Background Data: Liver function and morphology are crucial for survival of patients suffering from trauma, operations, or infections. Insulin decreased mortality and prevented the incidence of multiorgan failure in critically ill patients., Methods: Rats received a thermal injury and were randomly divided into the insulin or control group. Our outcome measures encompassed the effect of insulin on hepatic proteins, hepatic pro- and anti-inflammatory cytokines mRNA and proteins, hepatocyte proliferation, including Bcl-2 and hepatocyte apoptosis, with caspases-3 and caspases-9., Results: Insulin significantly improved hepatic protein synthesis by increasing albumin and decreasing c-reactive protein and fat (P < 0.05). Insulin decreased the hepatic inflammatory response signal cascade by decreasing hepatic pro-inflammatory cytokines mRNA and proteins IL-1beta and tumor necrosis factor at pretranslational levels. Insulin increased hepatic cytokine mRNA and protein expression of IL-2 and IL-10 at a pretranslational level when compared with controls (P < 0.05). Insulin increased hepatocyte proliferation along with Bcl-2 concentration, while decreasing hepatocyte apoptosis along with decreased caspases-3 and -9 concentration, thus improving liver morphology (P < 0.05)., Conclusions: Our data provide insight that insulin attenuates the inflammatory response by decreasing the pro-inflammatory and increasing the anti-inflammatory cascade, thus restoring hepatic homeostasis, which has been shown to be critical for organ function and survival of critically ill patients.
- Published
- 2004
- Full Text
- View/download PDF
37. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation.
- Author
-
Guba M, Graeb C, Jauch KW, and Geissler EK
- Subjects
- Adrenal Cortex Hormones adverse effects, Adrenal Cortex Hormones therapeutic use, Calcineurin Inhibitors, Cyclosporine adverse effects, Cyclosporine therapeutic use, Humans, Sirolimus adverse effects, Sirolimus therapeutic use, Antineoplastic Agents therapeutic use, Carcinogens, Immunosuppressive Agents adverse effects, Immunosuppressive Agents therapeutic use, Transplantation Immunology
- Abstract
Development of cancer is a feared, and increasingly apparent, complication of long-term immunosuppressive therapy in transplant recipients. In addition to the need to reduce cancer occurrence in these patients, therapeutic protocols are lacking to simultaneously attack the malignancy and protect the allograft when neoplasms do occur. In this overview, we present the current literature regarding the pro- and anti-neoplastic effects of immunosuppressive agents on cancer growth and development. Recent experimental findings are paving the way for new therapeutic strategies aimed at both protecting an allograft from immunologic rejection and addressing the problem of cancer in this high-risk population.
- Published
- 2004
- Full Text
- View/download PDF
38. Continuous infusion of nitroglycerin improves pulmonary graft function of non-heart-beating donor lungs.
- Author
-
Loehe F, Preissler G, Annecke T, Bittmann I, Jauch KW, and Messmer K
- Subjects
- Animals, Infusions, Intravenous, Microscopy, Electron, Scanning, Models, Animal, Nitroglycerin administration & dosage, Organ Preservation methods, Reperfusion methods, Respiratory Function Tests, Swine, Heart Arrest, Lung ultrastructure, Lung Transplantation physiology, Nitroglycerin therapeutic use, Reperfusion Injury prevention & control, Tissue Donors
- Abstract
Background: The warm ischemic period of lungs harvested from a non-heart-beating donor (NHBD) results in an increased ischemia-reperfusion injury after transplantation. The intravenous application of nitroglycerin (NTG), a nitric oxide (NO) donor, proved to be beneficial during reperfusion of lung grafts from heart-beating donors. The objective of the present study was to investigate the effect of nitroglycerin on ischemia-reperfusion injury after transplantation of long-term preserved NHBD-lungs., Methods: Sixteen pigs (body weight, 20-30 kg) underwent left lung transplantation. In the control group (n=5), lungs were flushed (Perfadex, 60 mL/kg) and harvested immediately after cardiac arrest. In the NHBD group (n=5) and the NHBD-NTG group (n=6), lungs were flushed 90 min (warm ischemia) after cardiac arrest. After a total ischemia time of 19 hr, lungs were reperfused and graft function was observed for 5 hr. Recipient animals in the NHBD-NTG group received 2 microg/kg/min of NTG administered intravenously during the observation period starting 5 min before reperfusion. Tissue specimens and bronchoalveolar lavage fluid (BALF) were obtained at the end of the observation period., Results: Compared with the control group, pulmonary gas exchange was significantly impaired in the NHBD group, whereas graft function in the NHBD-NTG group did not change. Leukocyte fraction and protein concentration in the BALF and histologic alteration of the NHBD-NTG group were not different from controls., Conclusions: Continuous infusion of NTG in the early reperfusion period improves pulmonary graft function of NHBD lungs after long-term preservation. The administration of an NO donor during reperfusion may favor the use of NHBD lungs to alleviate the critical organ shortage in lung transplantation.
- Published
- 2004
- Full Text
- View/download PDF
39. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice.
- Author
-
Koehl GE, Andrassy J, Guba M, Richter S, Kroemer A, Scherer MN, Steinbauer M, Graeb C, Schlitt HJ, Jauch KW, and Geissler EK
- Subjects
- Adenocarcinoma complications, Animals, Colonic Neoplasms complications, Cyclosporine pharmacology, Drug Therapy, Combination, Graft Rejection complications, Graft Rejection immunology, Immunosuppressive Agents pharmacology, Male, Melanoma complications, Melanoma drug therapy, Mice, Mice, Inbred BALB C, Mice, Inbred C3H, Mice, Inbred C57BL, Mice, SCID, Skin Neoplasms complications, Skin Neoplasms drug therapy, Transplantation, Homologous, Adenocarcinoma drug therapy, Antibiotics, Antineoplastic pharmacology, Colonic Neoplasms drug therapy, Graft Rejection drug therapy, Heart Transplantation, Sirolimus pharmacology
- Abstract
Cancer is an increasingly recognized problem associated with immunosuppression. Recent reports, however, suggest that the immunosuppressive agent rapamycin has anti-cancer properties that could address this problem. Thus far, rapamycin's effects on immunity and cancer have been studied separately. Here we tested the effects of rapamycin, versus cyclosporine A (CsA), on established tumors in mice simultaneously bearing a heart allograft. In one tumor-transplant model, BALB/c mice received subcutaneous syngenic CT26 colon adenocarcinoma cells 7 days before C3H ear-heart transplantation. Rapamycin or CsA treatment was initiated with transplantation. In a second model system, a B16 melanoma was established in C57BL/6 mice that received a primary vascularized C3H heart allograft. In vitro angiogenic effects of rapamycin and CsA were tested in an aortic ring assay. Results show that CT26 tumors grew for 2 weeks before tumor complications occurred. However, rapamycin protected allografts, inhibited tumor growth, and permitted animal survival. In contrast, CsA-treated mice succumbed to advancing tumors, albeit with a functioning allograft. Rapamycin's antitumor effect also functioned in severe combined immunodeficient BALB/c mice. Similar effects of the drugs occurred with B16 melanomas and primary vascularized C3H allografts in C57BL/6 mice. Furthermore, in this model, rapamycin inhibited the tumor growth-enhancing effects of CsA. Moreover, in vitro experiments showed that CsA promotes angiogenesis by a transforming growth factor-beta-related mechanism, and that this effect is abrogated by rapamycin. This study demonstrates that rapamycin simultaneously protects allografts from rejection and attacks tumors in a complex transplant-tumor situation. Notably, CsA protects allografts from rejection, but cancer progression is promoted in transplant recipients.
- Published
- 2004
- Full Text
- View/download PDF
40. The antineoplastic drug Paclitaxel has immunosuppressive properties that can effectively promote allograft survival in a rat heart transplant model.
- Author
-
Tange S, Scherer MN, Graeb C, Weiss T, Justl M, Frank E, Andrassy J, Jauch KW, and Geissler EK
- Subjects
- Animals, Male, Paclitaxel blood, Rats, Rats, Inbred ACI, Rats, Inbred Lew, Antineoplastic Agents, Phytogenic pharmacology, Graft Survival drug effects, Heart Transplantation, Immunosuppressive Agents pharmacology, Paclitaxel pharmacology
- Abstract
Introduction: Recurrent and de novo neoplasms are ominous risk factors for transplant patients. In particular, when organ transplantation is attempted to cure isolated cancers, conventional immunosuppression likely promotes cancer reestablishment. Therefore, drugs with both immunosuppressive and antineoplastic activity are needed. We show that the anticancer agent paclitaxel may fulfill these diverse expectations., Methods: Heterotopic heart transplantation was performed in the ACI-to-Lewis or Lewis-to-ACI rat-strain combination and paclitaxel was injected i.p. daily (days 0-14) at doses from 0.75-1.5 mg/kg. Serum cytotoxic antidonor antibody levels were measured using a complement-mediated cell cytotoxicity assay. In vitro, the effect of paclitaxel on Lewis lymphocyte viability and apoptosis was determined. Also, Lewis lymphocytes preconditioned with irradiated ACI cells+/-paclitaxel, were restimulated with ACI cells and tested for cytotoxic T cell (CTL) activity and interleukin-2 (IL-2) production., Results: Paclitaxel promoted heart allograft survival in a dose-dependent manner in both high- and low-responder transplant combinations. Furthermore, low-doses of paclitaxel (0.75-1.0 mg/kg) and cyclosporine (1 mg/kg) in combination synergistically increased transplant survival. Immunologically, paclitaxel markedly reduced the antidonor cytotoxic antibody response. In vitro, nearly 90% of prestimulated lymphocytes were killed by paclitaxel and cells became positive for the apoptosis marker, annexin-V. Furthermore, paclitaxel reduced CTL activity and IL-2 production after alloantigen rechallenge., Conclusion: Paclitaxel, a clinically proven antineoplastic agent, also has potent immunosuppressive properties in rodent organ transplantation. This drug could be extremely valuable in transplant situations where de novo cancer develops, or when organ transplantation is performed to treat isolated, but typically recurrent, neoplasms.
- Published
- 2002
- Full Text
- View/download PDF
41. IGF-I/BP-3 administration preserves hepatic homeostasis after thermal injury which is associated with increases in no and hepatic NF-kappa B.
- Author
-
Jeschke MG, Herndon DN, Vita R, Traber DL, Jauch KW, and Barrow RE
- Subjects
- Animals, Apoptosis, Aspartate Aminotransferases, Burns pathology, Burns physiopathology, Cell Division drug effects, Hepatocytes pathology, Homeostasis drug effects, In Situ Nick-End Labeling, Liver pathology, Male, NF-kappa B metabolism, Nitric Oxide blood, Rats, Rats, Sprague-Dawley, Insulin-Like Growth Factor Binding Protein 3 pharmacology, Insulin-Like Growth Factor I pharmacology, Liver injuries, Liver metabolism, Wounds and Injuries metabolism
- Abstract
After a severe trauma, such as a cutaneous thermal injury, an increase in hepatocyte apoptosis has been associated with hepatocyte damage and impairment in hepatic function. Insulinlike growth factor-I (IGF-I) exerts antiapoptotic effects in several organs, thus improving organ homeostasis. The purpose of the present study was to determine whether IGF-I in combination with its principle binding protein-3 (BP-3) attenuates liver damage after a burn and whether this attenuation is through signals of the apoptotic-proliferative axis of hepatocytes. Sprague-Dawley rats (56 males) received a 60% total body surface area third-degree scald burn and were randomly divided to receive either rhlGF-I/BP3 (10 mg/kg/day s.c.) or saline (control). Serum aspartate transaminase (AST) and nitric oxide (NO), and hepatocyte proliferation and apoptosis, were measured on postburn days 1, 2, 5, and 7. Hepatic interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha) mRNA and hepatic nuclear-factor kappa B (NF-kappa B) were determined at 1 and 2 days postburn. IGF-I/BP-3 decreased serum AST and increased serum NO at 1, 2, and 5 days after burn when compared with controls (P < 0.05). IGF-I/BP-3 increased hepatocyte proliferation on the first day after burn and decreased hepatocyte apoptosis at day 7 postburn when compared with controls (P < 0.05). IGF-I/BP-3 decreased hepatic IL-1 beta and TNF-alpha mRNA 1 day after burn (P < 0.05). IGF-I/BP-3 further increased hepatic NF-kappa B concentration 1 and 2 days postburn when compared with controls (P < 0.05). Recombinant hIGF-I in combination with its principle binding protein conserves hepatic homeostasis, which is associated with a transient increase in hepatocyte proliferation and decrease in hepatocyte apoptosis possibly through NO and hepatic NF-kappa B.
- Published
- 2001
- Full Text
- View/download PDF
42. Impact of polynitroxylated albumin (PNA) and tempol on ischemia/reperfusion injury: intravital microscopic study in the dorsal skinfold chamber of the Syrian golden hamster.
- Author
-
Steinbauer M, Guba M, Büchner M, Farkas S, Anthuber M, and Jauch KW
- Subjects
- Albumins administration & dosage, Albumins pharmacology, Animals, Antioxidants pharmacology, Antioxidants therapeutic use, Blood Viscosity, Cell Adhesion, Coloring Agents, Cricetinae, Cyclic N-Oxides pharmacology, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical, Drug Synergism, Fluorescent Dyes analysis, Fluorescent Dyes pharmacokinetics, Free Radical Scavengers pharmacology, Ischemia pathology, Leukocytes pathology, Mesocricetus, Microscopy, Fluorescence, Nitric Oxide Donors pharmacology, Nitrogen Oxides administration & dosage, Nitrogen Oxides pharmacology, Oxidative Stress, Prostheses and Implants, Reperfusion Injury drug therapy, Reperfusion Injury pathology, Skin pathology, Spin Labels, Albumins therapeutic use, Cyclic N-Oxides therapeutic use, Free Radical Scavengers therapeutic use, Ischemia drug therapy, Nitric Oxide Donors therapeutic use, Nitrogen Oxides therapeutic use, Reperfusion Injury prevention & control, Skin blood supply
- Abstract
Nitric oxide-releasing drugs have been shown to reduce ischemia/reperfusion (I/R) injury by acting as radical scavengers. However, their therapeutic application is hampered by specific side effects and rapid bioreduction in vivo. The half-life and antioxidant activity of nitroxides may be enhanced by their covalent binding to human serum albumin, resulting in polynitroxyl albumin (PNA). Thus, PNA may represent a novel antioxidative drug. The objectives of this study were to elucidate 1) whether PNA is able to diminish I/R injury; 2) the most effective dose of PNA in vivo; and 3) whether the addition of the nitroxide tempol enhances and/or prolongs the effect of PNA. Experiments were performed using a 4-h tourniquet-induced ischemia model in the hamster dorsal skinfold chamber. In the first part, five groups (n = 6) of animals received an infusion of 1) 1% body weight (b.w.) saline (0.9%); 2) 0.5% b.w. albumin (20%); 3) 0.5% b.w. PNA (20%); 4) 1% b.w. albumin (20%); and 5) 1% b.w. PNA (20%) 15 min prior to reperfusion. In the second part of the study, tempol (17 mg/mL) was added either to albumin or PNA (1:9), and 0.5% b.w. of this solution was infused (Group 6: tempol + albumin 0.5% b.w.; Group 7: tempol + PNA 0.5% b.w.). Intravital fluorescence microscopy allowed for quantification of functional capillary density (FCD), leukocyte adherence, extravasation of fluorescein isothiocyanate-labeled Dextran and non-viable (Propidium-positive) cell count prior to ischemia and 0.5 h, 2 h, and 24 h after reperfusion. PNA and--to a lesser extent albumin--effectively reduced postischemic microvascular perfusion failure, leukocyte adhesion, and tissue injury. PNA was most effective in the dose 1% b.w. Although free oxygen radical scavenging seems to be an underlying mechanism leading to the beneficial effects of PNA on I/R injury, hemodilution and known radical scavenging properties of pure albumin contribute in part to the observed effects. Although the combination of tempol and PNA revealed further short-term effects on microvascular perfusion and leukocyte adhesion, it did not result in a long-term improvement of tissue injury.
- Published
- 2000
- Full Text
- View/download PDF
43. Differential effects of short-term ace- and AT1-receptor inhibition on postischemic injury and leukocyte adherence in vivo and in vitro.
- Author
-
Guba M, Steinbauer M, Büchner M, Frölich D, Farkas S, Jauch KW, and Anthuber M
- Subjects
- Animals, Capillaries drug effects, Cell Adhesion, Cell Death drug effects, Cell Hypoxia, Cell Line drug effects, Cricetinae, Enalapril pharmacology, Endothelium, Vascular cytology, Endothelium, Vascular drug effects, Hemodynamics, Hemorheology, Humans, Interleukin-1 pharmacology, Leukocytes cytology, Losartan pharmacology, Mesocricetus, Neutrophils cytology, Neutrophils drug effects, Receptor, Angiotensin, Type 1, Receptor, Angiotensin, Type 2, Receptors, Angiotensin metabolism, Reperfusion Injury drug therapy, Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors pharmacology, Leukocytes metabolism, Peptidyl-Dipeptidase A metabolism, Reperfusion Injury metabolism
- Abstract
There is recent evidence that angiotensin-converting enzyme (ACE) inhibition reduces postischemic injury and angiotensin II receptor inhibition may have similar effects. We therefore further characterized the role of ACE- vs. AT1-receptor inhibition on cell injury and temporal association of leukocyte endothelial interaction in response to ischemia-reperfusion. A combined in vivo and in vitro study comparing the ACE inhibitor enalapril and the AT1-receptor antagonist losartan was performed. The extent and temporal correlation of cellular damage (propidium-iodide staining), microvascular perfusion failure and leukocyte-endothelial interaction (leukocyte adherence) were investigated by means of intravital microscopy, after the application of hemodynamically ineffective doses of enalapril and losartan (5 mg/kg). A hamster dorsal skinfold model with a 4-h tourniquet ischemia was used. In vitro, the effect of enalapril and losartan on polymorphonuclear cell (PMN) adherence, as well as adhesion molecule expression (ICAM-1, VCAM-1), on hypoxia- or IL-1beta-stimulated endothelial cells (HUVEC) was assessed using a PMN-adhesion assay and flow cytometry, respectively. Ischemia-reperfusion responses revealed a biphasic pattern, comprised of an early phase (30 min) of acute cellular damage and microvascular perfusion failure, followed by a late increase (240 min) in leukocyte adherence in vivo. Enalapril significantly reduced early cellular damage, microvascular perfusion failure, and leukocyte adherence in response to ischemia-reperfusion. Conversely, AT1 receptor inhibition with losartan proved to be ineffective at attenuating postischemic microcirculatory disorders (leukocyte-endothelial interactions, microvascular perfusion failure) and aggravated cellular injury. In vitro, enalapril reduced PMN adherence and ICAM-1 and VCAM-1 expression, while losartan was ineffective in the same respect. Following ischemia-reperfusion injury, ACE- versus AT1-receptor inhibition induce differential effects concerning the extent and temporal association of cell injury and leukocyte-endothelial interaction. The use of enalapril combines the beneficial effects of preventing cell and vascular injury immediately after reperfusion, with a delayed inhibition of the inflammatory response. Since the AT1-receptor inhibitor losartan did not mimic effects obtained with ACE inhibition, it is conceivable that the responses in ischemia-reperfusion are mediated by a non-angiotensin II-AT1 receptor-dependent mechanism.
- Published
- 2000
- Full Text
- View/download PDF
44. Effects of the combined thromboxane receptor antagonist and synthase inhibitor DTTX-30 on intestinal O2-exchange and energy metabolism during hyperdynamic porcine endotoxemia.
- Author
-
Matejovic M, Radermacher P, Zülke C, Vlatten A, Altherr J, Brinkmann A, Brückner UB, Jauch KW, Georgieff M, and Träger K
- Subjects
- Animals, Carbon Dioxide metabolism, Endotoxemia metabolism, Endotoxins toxicity, Female, Lipopolysaccharides toxicity, Male, Oxyhemoglobins metabolism, Swine, Time Factors, Chlorobenzenes pharmacology, Endotoxemia physiopathology, Energy Metabolism drug effects, Intestinal Mucosa physiopathology, Intestines physiopathology, Oxygen Consumption drug effects, Pyridines pharmacology, Receptors, Thromboxane antagonists & inhibitors, Thromboxane-A Synthase antagonists & inhibitors
- Abstract
Sepsis may lead to deranged thromboxane-prostacyclin ratio with consecutive organ dysfunction. Because of the suggested role of the gut in the pathogenesis of septic shock and multiple organ failure, we investigated the effects of the novel dual thromboxane synthase inhibitor and receptor antagonist DTTX-30 (TRASI) on intestinal tissue perfusion, O2 kinetics, and energy metabolism over 24 h of hyperdynamic, normotensive porcine endotoxemia. Before, 12, 18, and 24 h after starting continuous i.v. endotoxin (LPS), we measured portal venous (PV) blood flow, intestinal oxygen extraction (iO2ER), intracapillary hemoglobin O2 saturation (HbO2%) of the ileal wall, intramucosal ileal PCO2, PV lactate-pyruvate (L-P) ratio, and plasma levels of thromboxane and prostacyclin. Treatment with TRASI (0.12 mg/kg i.v. bolus injection followed by an infusion of 0.29 mg/kg/h) initiated after 12 h of LPS infusion markedly reduced the plasma thromboxane levels and attenuated the LPS-induced fall in systemic vascular resistance, resulting in hemodynamic stabilization. TRASI did not influence the LPS-induced increase in PV blood flow nor intracapillary HbO2%, thus reflecting unchanged microcirculatory O2 availability and decreased iO2ER, possibly because of reduced O2 requirements. Nevertheless, TRASI prevented the LPS-induced increase in the PV L-P ratio, attenuated the progression of the ileal mucosal-arterial PCO2 gap, and tended to attenuate the gradual fall of PV pH. Hence, compounds like TRASI may beneficially influence LPS-related derangements of gut energy metabolism.
- Published
- 2000
- Full Text
- View/download PDF
45. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen)
- Author
-
Lorenz M, Müller HH, Schramm H, Gassel HJ, Rau HG, Ridwelski K, Hauss J, Stieger R, Jauch KW, Bechstein WO, and Encke A
- Subjects
- Adult, Aged, Chemotherapy, Adjuvant, Female, Fluorouracil administration & dosage, Hepatic Artery, Humans, Infusions, Intra-Arterial, Leucovorin administration & dosage, Liver Neoplasms mortality, Liver Neoplasms secondary, Male, Middle Aged, Survival Rate, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Colorectal Neoplasms pathology, Liver Neoplasms drug therapy, Liver Neoplasms surgery
- Abstract
Objective: To determine the impact of adjuvant hepatic arterial infusion (HAI) on survival relative to resection alone in patients with radical resection of colorectal liver metastases., Summary Background Data: Nearly 40% to 50% of all patients with colorectal carcinoma develop liver metastases. Curative resection results in a 5-year survival rate of 25% to 30%. Intrahepatic recurrence occurs after a median of 9 to 12 months in up to 60% of patients. The authors hypothesized that adjuvant intraarterial infusion of 5-fluorouracil (5-FU) might decrease the rate of intrahepatic recurrence and improve survival in patients with radical resection of colorectal liver metastases., Methods: Between April 5, 1991, and December 31, 1996, patients with colorectal liver metastases from 26 hospitals were stratified by the number of metastases and the site of the primary tumor and randomized to resection of the liver metastases followed by adjuvant HAI of 5-FU (1000 mg/m2 per day for 5 days as a continuous 24-hour infusion) plus folinic acid (200 mg/m2 per day for 5 days as a short infusion), or liver resection only., Results: The first planned intention-to-treat interim analysis after inclusion of 226 patients and 91 events (deaths) showed a median survival of 34.5 months for patients with adjuvant therapy versus 40.8 months for control patients. The median time to progression was 14.2 months for the chemotherapy group versus 13.7 months for the control group. Grade 3 and 4 toxicities (World Health Organization), mainly stomatitis (57.6%) and nausea (55.4%), occurred in 25.6% of cycles and 62.9% of patients., Conclusion: According to this planned interim analysis, adjuvant HAI, when used in this dose and schedule in patients with resection of colorectal liver metastases, reduced the risk of death at best by 15%, but at worst the risk of death was doubled. Thus, the chance of detecting an expected 50% improvement in survival by the use of HAI was only 5%. Patient accrual was therefore terminated.
- Published
- 1998
- Full Text
- View/download PDF
46. Effect of glucagon on protein synthesis in human rectal cancer in situ.
- Author
-
Hartl WH, Demmelmair H, Jauch KW, Koletzko B, and Schildberg FW
- Subjects
- Aged, Glucagon pharmacology, Humans, Middle Aged, Neoplasm Proteins drug effects, Carcinoma in Situ metabolism, Glucagon physiology, Neoplasm Proteins biosynthesis, Rectal Neoplasms metabolism
- Abstract
Objective: The purpose of this study was to determine the effect of glucagon or placebo on the rate of tumor fractional protein synthesis in situ in patients with localized rectal cancer who were not malnourished, demonstrated normal glucagon concentrations, and could therefore be used as a model to study the glucagon effect., Summary Background Data: Cancer cachexia is associated with an increased concentration of counterregulatory hormones, including glucagon. This altered hormonal milieu may not only contribute to malnutrition, but also promote tumor growth, because previous experimental work suggests that glucagon can cause human colorectal tumor cells to proliferate. Corresponding mechanisms in vivo have, thus far, not been investigated., Methods: Advanced mass spectrometry techniques (capillary gas chromatography [GC]/combustion isotope ratio mass spectrometry [IRMS]) were used to determine directly the incorporation rate of 1-[13C]-leucine into tissue protein. Because GC/IRMS requires only a small sample volume, three consecutive endoscopic biopsies could be obtained from the same tumor to determine isotopic enrichments at baseline, after a 4-hour glucagon infusion (3 ng/kg/min), or after placebo., Results: In patients with localized rectal cancer, glucagon caused the tumor fractional protein synthetic rate to double (2.25+/-0.49 %/hr, p < 0.05 vs. 1.16+/-0.30 basal). In contrast, tumor protein synthesis declined over time in controls (placebo) (0.67+/-0.09 %/hr, p < 0.05 vs. 1.11+/-0.16 basal)., Conclusions: Tumor protein synthesis and growth can be stimulated by glucagon in situ. Therefore, elevated glucagon concentrations in cachectic cancer patients should be considered detrimental and attempts made to prevent this specific response of the body to the malignant disease.
- Published
- 1998
- Full Text
- View/download PDF
47. Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer.
- Author
-
Heiss MM, Allgayer H, Gruetzner KU, Babic R, Jauch KW, and Schildberg FW
- Subjects
- Aged, Alkaline Phosphatase metabolism, Bone Marrow Examination, Female, Gastrectomy, Humans, Immunohistochemistry, Male, Middle Aged, Multivariate Analysis, Plasminogen Activator Inhibitor 1 metabolism, Prognosis, Prospective Studies, Regression Analysis, Stomach Neoplasms mortality, Stomach Neoplasms surgery, Survival Analysis, Urokinase-Type Plasminogen Activator metabolism, Biomarkers, Tumor metabolism, Bone Marrow Neoplasms metabolism, Bone Marrow Neoplasms secondary, Neoplasm Proteins metabolism, Neoplasm Staging methods, Stomach Neoplasms metabolism, Stomach Neoplasms pathology
- Abstract
Objective: To investigate whether extended staging, including biologic grading and aspects of an early systemic disease component, would give additional prognostic information on patients with curatively resected gastric cancer., Background: Tumor-associated proteolytic mechanisms have been shown to be essential for invasion and metastasis. The urokinase-type plasminogen activator (uPA) system is of major biologic impact, but different interactive proteases and inhibitors with modulating effects also must be considered. The detection of early tumor cell dissemination indicates the systemic character of a primarily local gastric cancer. The confrontation of the organism with these cells determines the often unpredictable course of an individual tumor after presumed curative primary treatment., Methods: In a prospective study of 247 consecutive patients with gastric cancer, detection of disseminated tumor cells in bone marrow aspirates was immunocytochemically performed in 180 patients. The expression of uPA, activators of uPA (cathepsin D, antithrombin III), uPA substrates (plasminogen, matrix-metalloproteinase 2 [collagenase IV, 72 kD; MMP-2]), uPA/plasmin inhibitors (plasminogen activator inhibitor type 1 and 2 [PAI-1, PAI-2], alpha1-antitrypsin, alpha2-antiplasmin), uPA receptor (uPA-R), and parameters of the uPA-R cycle (alpha2-macroglobulin, alpha1-antichymotrypsin) could be determined immunohistochemically and were scored semiquantitatively in 203 patients. Kaplan-Meier statistical techniques and multivariate Cox regression models were used for prognostic analyses., Results: In multivariate analysis considering all the established risk factors, disease-free survival was independently predicted by PAI-1 (relative risk 2.21, 1.32-3.73) and cathepsin D (relative risk 2.98, 1.28-6.91) besides pT, pN, and extended resection. Tumor cell dissemination was found to be an additional prognostic factor in early tumor stages (pT1, T2) and lymphnode-negative patients. Stepwise regression analysis revealed an extended staging system with new risk groups. Node-positive, curatively resected pT1/2 patients with low expression of PAI-1 had a favorable prognosis (mean recurrence-free survival [MRT] 54.84 months), similar to that of node-negative patients (MRT 54.76 months). In node-negative, curatively resected pT1/2 patients, detection of bone marrow tumor cells and high expression of PAI-1 defined a subgroup with a steep decrease of prognosis (MRT 36.60 months), which was worse than that of node-positive patients (MRT 45.81)., Conclusion: This new staging model gives better prognostic differentiation of subgroups, which should be considered in future adjuvant therapy protocols. In addition, it indicates that the uPA system might be a future therapeutic target.
- Published
- 1997
- Full Text
- View/download PDF
48. Modulation of immune response by blood transfusion: evidence for a differential effect of allogeneic and autologous blood in colorectal cancer surgery.
- Author
-
Heiss MM, Fraunberger P, Delanoff C, Stets R, Allgayer H, Ströhlein MA, Tarabichi A, Faist E, Jauch KW, and Schildberg FW
- Subjects
- Adjuvants, Immunologic blood, Adult, Aged, Antibody Specificity, Blood Transfusion, Autologous, Colorectal Neoplasms surgery, Colorectal Surgery, Cytokines blood, Female, Humans, Immunoglobulins blood, Immunoglobulins drug effects, Male, Middle Aged, Tetanus Toxoid immunology, Transplantation, Homologous, Antibody Formation immunology, Blood Transfusion
- Abstract
Even though blood transfusion-associated immunomodulatory effects have been reported, the basic immune mechanism is still not understood. Data from studies on the clinical effects of allogeneic blood-induced immunosuppression are contradictory. However, there are indications that autologous blood transfusion is not immunologically neutral but has intrinsic immunomodulatory potential. Therefore we investigated in vivo different immunological mediators in 56 randomized patients of a study comparing autologous and allogeneic blood transfusion in colorectal cancer surgery. Soluble IL-2 receptor, which is an indicator of general immune activation and the following immunologic refractory phase, indicated immunosuppression was more elevated at the seventh postoperative day in patients with allogeneic transfusions (p = .013) and autologous transfusions (p = .0003). The immunologic determination of TNF-alpha showed a significant postoperative increase in patients with autologous transfusions only (p = .0031). However, postoperative increase of soluble TNF-receptors p55 and p75 was also significant in patients transfused with allogenic blood (p = .022; p = .0014). The response to tetanus toxoid vaccination, an indicator of humoral immunity, was higher in patients transfused with allogeneic rather than autologous blood (p = .082), whereas responses of patients with autologous transfusions were even lower than in nontransfused patients. The reciprocal was already found for cell-mediated immunity determined by epicutaneously tested delayed-type hypersensitivity-reactions. IL-10 levels, an indicator of cellular immunosuppression, were determined in 27 additional patients before operation, immediately postoperative, and at the seventh postoperative day. IL-10 was found elevated immediately postoperative in allogeneic (p = .011) and nontransfused patients only (p = .042). The data from this study substantiate recent findings of a different immunomodulatory potential of allogeneic and autologous blood transfusion. They furthermore support the hypothesis that autologous blood transfusion does not contain immunologically neutral effects of allogeneic blood, but itself exerts an immunomodulatory effect.
- Published
- 1997
- Full Text
- View/download PDF
49. In situ splitting of cadaveric livers. The ultimate expansion of a limited donor pool.
- Author
-
Rogiers X, Malagó M, Gawad K, Jauch KW, Olausson M, Knoefel WT, Gundlach M, Bassas A, Fischer L, Sterneck M, Burdelski M, and Broelsch CE
- Subjects
- Adult, Cadaver, Child, Child, Preschool, Graft Survival, Humans, Liver Transplantation adverse effects, Liver Transplantation mortality, Middle Aged, Survival Rate, Liver Transplantation methods, Tissue and Organ Procurement methods
- Abstract
Objective: The authors evaluate the safety, applicability, and effectiveness of a new technique for split-liver transplantation., Summary Background Data: Split-liver transplantation offers an attractive way to increase the donor pool for cadaveric liver transplantation. The application of this concept has been hampered by inferior patient and graft survivals and higher complication rates. Without supportive data, the concern about increasing biliary leakage and poor initial graft function persisted. The authors focused on the causes of these complications by presenting a new technique to eliminate these problems., Methods: Liver splitting was performed in the heart-beating cadaveric organ donor, using the technique described for procurement of the left lateral lobe of a live donor. A detailed description of the technique is presented. A retrospective review of the first 14 transplantations resulting from 7 in situ splitting procedures was collected. The results were compared with 19 conventional split-liver transplants performed during the same period., Results: Six-month patient and graft survivals after in situ split-liver transplantation were 92.8% and 85.7%, respectively. Biliary complications were absent. Postoperative courses were mostly uneventful and characterized by lower peak transaminase levels compared with standard techniques. Early graft function of extrahepatic organs procured simultaneously was excellent., Conclusions: In situ split-liver transplantation provides superior results, related mainly to reduction of cold ischemic damage of the grafts and avoidance of biliary complications. In situ split-liver transplantation renders graft reduction alone obsolete and opens a donor pool for adults to receive right lobes safely. It allows for long-distance sharing between pediatric and adult liver transplant units because the procedure abolishes ex situ benching and prolonged ischemia time and provides two anatomically perfect grafts with hemostasis accomplished.
- Published
- 1996
- Full Text
- View/download PDF
50. Conditioning of liver grafts by donor bolus pretreatment with epoprostenol.
- Author
-
Anthuber M, Farkas S, Rihl M, Menger MD, Jauch KW, Schildberg FW, and Messmer K
- Subjects
- Animals, Blood Pressure drug effects, Cell Adhesion drug effects, Leukocytes cytology, Liver blood supply, Liver cytology, Liver Transplantation immunology, Male, Perfusion, Rats, Rats, Inbred Lew, Epoprostenol therapeutic use, Liver Transplantation methods, Platelet Aggregation Inhibitors therapeutic use
- Abstract
Despite improved preservation methods, graft dysfunction after liver transplantation continues to contribute considerably to postoperative morbidity and mortality. In clinical and experimental studies prostaglandin (PG)I2 analogs proved effective in the treatment of liver damage of different origin. Using in vivo fluorescence microscopy in a rat liver transplantation model, we studied the effect of donor bolus pretreatment with the PGI2 analog epoprostenol on hepatic graft revascularization. After epoprostenol bolus pretreatment (group 1: liver transplantation/PGI2), perfusion of liver sinusoids after reperfusion was significantly improved as compared with untreated donor livers (group 2: liver transplantation (95.2+/-0.6% vs. 75.3+/-3.8%, mean +/- SEM; P=0.001) and epoprostenol was found almost in the range of that in normal nontransplanted livers (99.4+/-0.2%). In addition, leukocyte adherence in liver lobules (21.0+/-3.5 vs. 115+/-11.5 n/lobule; P=0.001) and postsinusoidal venules (23.0+/-3.8 vs. 113+/-11.3 n/mm2 endothelial surface; P=0.002) was significantly reduced in the pretreated grafts. Bile production in the recipient was significantly increased by epoprostenol pretreatment of the donor (1.88+/-0.4 vs. 0.63+/-0.13 g/100 g liver*1 hr; P=0.015), indicating restored liver function. These results suggest that the prostacyclin analog epoprostenol is effective in preconditioning the graft prior to transplantation, i.e., improving preservation and increasing graft resistance to ischemia/reperfusion injury. Thus, favorable effects on early graft function after clinical liver transplantation may be achieved by introducing epoprostenol pretreatment into the harvesting procedure.
- Published
- 1996
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.